


L1 HAS NO ANSWERS  
L1 STR



VAR G1=C/N  
VPA 10-2/1/6/5 U  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
GGCAT IS MCY HIQ AT 10  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RSPEC 1  
NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE


=> d his 12

(FILE 'REGISTRY' ENTERED AT 14:33:20 ON 19 AUG 2009)

L2 12899 SEA FILE=REGISTRY SSS FUL L1

=> d 13

L3 HAS NO ANSWERS  
L3 STR



VAR G1=H/C/N  
VPA 10-2/1/6/5 U  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
GGCAT IS MCY HIQ AT 10  
GGCAT IS UNS AT 12  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RSPEC 1  
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

=> search 13

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss  
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset


ENTER SUBSET L# OR (END):12  
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful  
FULL SUBSET SEARCH INITIATED 14:35:44 FILE 'REGISTRY'  
FULL SUBSET SCREEN SEARCH COMPLETED - 12694 TO ITERATE

100.0% PROCESSED 12694 ITERATIONS 1024 ANSWERS  
SEARCH TIME: 00.00.01

L4 1024 SEA SUB=L2 SSS FUL L3

=> d scan

L4 1024 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C23 H17 Cl2 F3 N4 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	46.40	46.62

FILE 'CAPLUS' ENTERED AT 14:36:06 ON 19 AUG 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Aug 2009 VOL 151 ISS 8  
FILE LAST UPDATED: 18 Aug 2009 (20090818/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPLUS family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> s 14

L5 78 L4

=> s 15 and py<=2004

25141382 PY<=2004

L6 41 L5 AND PY<=2004

=> s 16 and us/pc

1967837 US/PC

L7 17 L6 AND US/PC

=> d bib hitstr 1-17

L7 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:104220 CAPLUS

DN 144:192243

TI Preparation of annulated pyrazoles as gyrase inhibitors and uses thereof

IN Charifson, Paul; Deininger, David; Grillot, Anne-Laure; Liao, Yusheng;

Ronkin, Steven; Stamos, Dean P.; Perola, Emanuele; Wang, Tiansheng;

Letiran, Arnaud; Drumm, Joseph

PA USA

SO U.S. Pat. Appl. Publ., 219 pp., Cont.-in-part of U.S. Ser. No. 901,928.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 20060025424	A1	20060202	US 2004-971573	20041021 <--
	US 20060122196	A9	20060608		
	US 20040235886	A1	20041125	US 2004-767638	20040129 <--
	US 7495014	B2	20090224		
	US 20050038247	A1	20050217	US 2004-901928	20040729 <--
	US 7569591	B2	20090804		
	US 20050256136	A1	20051117	US 2004-986569	20041111 <--
PRAI	US 2003-443917P	P	20030131		
	US 2004-767638	A1	20040129		
	US 2004-901928	A2	20040729		
	WO 2004-US2541	A	20040129		
	US 2004-971573	A2	20041021		
	WO 2004-US34919	A2	20041021		

OS CASREACT 144:192243; MARPAT 144:192243

IT 797045-33-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of annulated pyrazoles as gyrase inhibitors)

RN 797045-33-1 CAPLUS

CN Urea, N-[5-(1,6-dihydro-6-oxo-1-phenyl-4-pyridazinyl)-7-(1H-pyrazol-1-yl)-1H-benzimidazol-2-yl]-N'-ethyl- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L7 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:100738 CAPLUS

DN 144:198849

TI Novel dosage form comprising modified-release and immediate-release active ingredients

IN Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar

PA India

SO U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060024365	A1	20060202	US 2005-134633	20050519 <--
	IN 2002MU00697	A	20040529	IN 2002-MU697	20020805 <--
	IN 193042	A1	20040626		
	IN 2002MU00699	A	20040529	IN 2002-MU699	20020805 <--
	IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
	IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
	US 20040096499	A1	20040520	US 2003-630446	20030729 <--
PRAI	IN 2002-MU697	A	20020805		
	IN 2002-MU699	A	20020805		
	IN 2003-MU80	A	20030122		
	IN 2003-MU82	A	20030122		
	US 2003-630446	A2	20030729		


IT 64420-40-2, Etibendazole

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel dosage form comprising modified-release and immediate-release active ingredients)

RN 64420-40-2 CAPLUS

CN Carbamic acid, N-[6-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]-1H-benzimidazol-2-yl]-, methyl ester (CA INDEX NAME)




OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L7 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2005:1224305 CAPLUS  
 DN 143:477961  
 TI Preparation of annulated pyrazoles as gyrase inhibitors and uses thereof  
 IN Charifson, Paul S.; Deininger, David D.; Grillot, Anne-Laure; Liao, Yusheng; Ronkin, Steven M.; Stamos, Dean; Perola, Emanuele; Wang, Tiansheng; Letiran, Arnaud; Drumm, Joseph  
 PA USA  
 SO U.S. Pat. Appl. Publ., 212 pp., Cont.-in-part of U.S. Ser. No. 971,573.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050256136	A1	20051117	US 2004-986569	20041111 <--
	US 20040235886	A1	20041125	US 2004-767638	20040129 <--
	US 7495014	B2	20090224		
	US 20050038247	A1	20050217	US 2004-901928	20040729 <--
	US 7569591	B2	20090804		
	US 20060025424	A1	20060202	US 2004-971573	20041021 <--
	US 20060122196	A9	20060608		
	WO 2006022773	A1	20060302	WO 2004-US34919	20041021
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2003-443917P	P	20030131		
	US 2004-767638	A2	20040129		
	US 2004-901928	A2	20040729		
	US 2004-971573	A2	20041021		
	WO 2004-US34919	A2	20041021		
	WO 2004-US2541	A	20040129		
OS	CASREACT 143:477961; MARPAT 143:477961				
IT	797045-33-1P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of annulated pyrazoles as gyrase inhibitors)				
RN	797045-33-1 CAPLUS				
CN	Urea, N-[5-(1,6-dihydro-6-oxo-1-phenyl-4-pyridazinyl)-7-(1H-pyrazol-1-yl)-				

1H-benzimidazol-2-yl]-N'-ethyl- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L7 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2005:140866 CAPLUS  
DN 142:219288  
TI Gyrase inhibitors and uses thereof  
IN Charifson, Paul S.; Deininger, David D.; Grillot, Anne-laure; Liao, Yusheng; Ronkin, Steven M.; Stamos, Dean; Perola, Emanuele; Wang, Tiansheng; Letiran, Arnaud; Drumm, Joseph  
PA USA  
SO U.S. Pat. Appl. Publ., 202 pp., Cont.-in-part of U.S. Ser. No. 767,638.  
CODEN: USXXCO

DT Patent  
LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050038247	A1	20050217	US 2004-901928	20040729 <--
	US 7569591	B2	20090804		
	US 20040235886	A1	20041125	US 2004-767638	20040129 <--
	US 7495014	B2	20090224		
	AU 2004261545	A1	20050210	AU 2004-261545	20040129
	CA 2513463	A1	20050210	CA 2004-2513463	20040129
	WO 2005012292	A1	20050210	WO 2004-US2541	20040129
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP	1592686	A1	20051109	EP 2004-775744	20040129
EP	1592686	B1	20090708		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP	2006528677	T	20061221	JP 2006-532271	20040129
NZ	541885	A	20090131	NZ 2004-541885	20040129
RU	2350612	C2	20090327	RU 2005-127328	20040129
AT	435859	T	20090715	AT 2004-775744	20040129
US	20060025424	A1	20060202	US 2004-971573	20041021 <--
US	20060122196	A9	20060608		
AU	2004322641	A1	20060302	AU 2004-322641	20041021
CA	2577758	A1	20060302	CA 2004-2577758	20041021
WO	2006022773	A1	20060302	WO 2004-US34919	20041021
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS,  
 MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD,  
 RU, TJ, TM

EP 1789419 A1 20070530 EP 2004-810009 20041021  
 EP 1789419 B1 20090617

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK

ZA 2007001629 A 20080925 ZA 2007-1629 20041021  
 AT 433980 T 20090715 AT 2004-810009 20041021  
 US 20050256136 A1 20051117 US 2004-986569 20041111 <--  
 IN 2005KN01402 A 20060818 IN 2005-KN1402 20050719  
 MX 2005008126 A 20060330 MX 2005-8126 20050729  
 KR 2006056270 A 20060524 KR 2005-714085 20050729  
 NO 2005003845 A 20050816 NO 2005-3845 20050816  
 HK 1087699 A1 20090605 HK 2006-107863 20060714  
 KR 2007048762 A 20070509 KR 2007-705024 20070228


PRAI US 2003-443917P P 20030131  
 US 2004-767638 A2 20040129  
 WO 2004-US2541 A 20040129  
 US 2004-901928 A2 20040729  
 US 2004-971573 A2 20041021  
 WO 2004-US34919 W 20041021

OS CASREACT 142:219288; MARPAT 142:219288

IT 797045-33-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
 (Biological study); PREP (Preparation)  
 (preparation of bacterial gyrase and/or topoisomerase IV inhibitors as  
 potential antibacterial agents)

RN 797045-33-1 CAPLUS

CN Urea, N-[5-(1,6-dihydro-6-oxo-1-phenyl-4-pyridazinyl)-7-(1H-pyrazol-1-yl)-  
 1H-benzimidazol-2-yl]-N'-ethyl- (CA INDEX NAME)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)

L7 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:1019781 CAPLUS

DN 142:6535


TI Preparation of benzimidazolyl ureas and related compounds as gyrase  
 inhibitors for treating bacterial infections

IN Charifson, Paul S.; Deininger, David D.; Grillot, Anne-Laure; Liao,  
 Yusheng; Ronkin, Steven M.; Stamos, Dean; Perola, Emanuele; Wang,  
 Tiansheng; Letiran, Arnaud; Drumm, Joseph

PA Vertex Pharmaceuticals Incorporated, USA

SO U.S. Pat. Appl. Publ., 148 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040235886	A1	20041125	US 2004-767638	20040129 <--
	US 7495014	B2	20090224		
	CN 1745077	A	20060308	CN 2004-80003086	20040129
	CN 100393714	C	20080611		
	ZA 2005005773	A	20060927	ZA 2005-5773	20040129
	US 20050038247	A1	20050217	US 2004-901928	20040729 <--
	US 7569591	B2	20090804		
	US 20060025424	A1	20060202	US 2004-971573	20041021 <--
	US 20060122196	A9	20060608		
	US 20050256136	A1	20051117	US 2004-986569	20041111 <--
	US 20090176771	A1	20090709	US 2008-246778	20081007 <--
PRAI	US 2003-443917P	P	20030131		
	US 2004-767638	A2	20040129		
	WO 2004-US2541	A	20040129		
	US 2004-901928	A2	20040729		
	US 2004-971573	A2	20041021		
	WO 2004-US34919	A2	20041021		
OS	MARPAT 142:6535				
IT	797045-33-1P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of benzimidazolyl ureas and related compds. as gyrase inhibitors for treating bacterial infections)				
RN	797045-33-1	CAPLUS			
CN	Urea, N-[5-(1,6-dihydro-6-oxo-1-phenyl-4-pyridazinyl)-7-(1H-pyrazol-1-yl)-1H-benzimidazol-2-yl]-N'-ethyl- (CA INDEX NAME)				



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)  
 RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2004:143142 CAPLUS  
 DN 140:199326  
 TI Preparation of benzimidazoles and benzothiazoles as inhibitors of p-38 map kinase for treating metastasis or rheumatoid arthritis  
 IN Bonjouklian, Rosanne; De Diego Gomez, Jose Eugenio; De Dios, Alfonso; Hamdouchi, Chafiq Hamdouchi; Li, Tiechao; Lopez De Uralde Garmendia, Beatriz; Vieth, Michal; York, Jeremy Schulenburg; Dally, Robert Dean; Del Prado Catalina, Miriam Filadelfa; Jaramillo, Carlos; Martin Cabrejas, Luisa Maria; Montero Salgado, Carlos; Pleite, Sheila; Sanchez-Martinez, Concepcion; Shepherd, Timothy Alan; Wikel, James Howard



PA Eli Lilly and Company, USA  
 SO PCT Int. Appl., 127 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014900	A1	20040219	WO 2003-US19890	20030731 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003256297	A1	20040225	AU 2003-256297	20030731 <--
	EP 1554272	A1	20050720	EP 2003-784749	20030731
	EP 1554272	B1	20061025		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	AT 343572	T	20061115	AT 2003-784749	20030731
	ES 2274302	T3	20070516	ES 2003-784749	20030731
	US 20050272791	A1	20051208	US 2005-522227	20050125 <--
	US 7320995	B2	20080122		
PRAI	EP 2002-380178	A	20020809		
	US 2002-421939P	P	20021028		
	WO 2003-US19890	W	20030731		
OS	MARPAT 140:199326				
IT	660432-27-9P, 1-Isopropylsulfonyl-2-amino-6-[1-benzyl-5-(2,4-difluorophenyl)-2-(methyl)imidazol-4-yl]benzimidazole				
	660432-69-9P, 1-Isopropylsulfonyl-2-amino-6-[2-(thien-2-yl)-5-(phenyl)imidazol-4-yl]benzimidazole				
	660432-74-6P, 1-Isopropylsulfonyl-2-amino-6-[2-(5-nitrothien-2-yl)-5-(phenyl)imidazol-4-yl]benzimidazole				
	660432-84-8P, 1-Isopropylsulfonyl-2-amino-6-[2-(4-nitrophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole				
	660432-90-6P, 1-Isopropylsulfonyl-2-amino-6-[2-[1-(tert-butoxycarbonyl)piperidin-4-yl]-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole				
	660432-91-7P, 1-Isopropylsulfonyl-2-amino-6-[2-[1-(benzyloxycarbonyl)piperidin-4-yl]-5-(phenyl)imidazol-4-yl]benzimidazole				
	660433-80-7P, 1-Isopropylsulfonyl-2-amino-6-[2-(2,6-difluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole				
	660433-82-9P, 1-Cyclopentylsulfonyl-2-amino-6-[2-(2,6-difluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole				
	660433-93-2P, 1-Isopropylsulfonyl-2-amino-6-[2-isopropyl-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole				
	660433-95-4P, 1-Isopropylsulfonyl-2-amino-6-[2-isopropyl-5-(phenyl)imidazol-4-yl]benzimidazole				
	660434-35-5P 660434-36-6P				
	660434-54-8P, 1-Isopropylsulfonyl-2-amino-6-[1-cyclohexyl-4-(phenyl)imidazol-5-yl]benzimidazole				
	660434-58-2P, 1-Isopropylsulfonyl-2-amino-6-[1-[4-[N-(tert-butoxycarbonyl)amino]cyclohexyl]-4-(phenyl)imidazol-5-yl]benzimidazole				
	660434-59-3P, 1-Isopropylsulfonyl-2-amino-6-[1-(1,4-dioxaspiro[4.5]decan-8-yl)-4-(phenyl)imidazol-5-yl]benzimidazole				
	660434-73-1P, 1-Isopropylsulfonyl-2-amino-6-[1-(4-methoxybenzyl)-4-(phenyl)imidazol-5-yl]benzimidazole				
	660434-87-7P, 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-4-(2-fluorophenyl)imidazol-5-				


yl]benzimidazole 660435-03-0P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(p-nitrophenyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660435-18-7P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(piperidin-4-yl)-5-(phenyl)imidazol-4-yl]benzimidazole 660435-21-2P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(piperidin-4-yl)-4-(phenyl)imidazol-5-yl]benzimidazole 660435-36-9P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(4-oxocyclohexyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660435-39-2P,  
 1-Isopropylsulfonyl-2-benzylamino-6-[4-(phenyl)imidazol-5-yl]benzimidazole 660435-45-0P,  
 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-bromo-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660435-46-1P,  
 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-(4-chlorophenyl)-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660435-50-7P,  
 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-(trimethylsilylethynyl)-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660435-53-0P,  
 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-(ethynyl)-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660435-63-2P,  
 1-Isopropylsulfonyl-2-amino-6-[1-cyclohexyl-2-bromo-4-phenylimidazol-5-yl]benzimidazole 660435-81-4P,  
 1-Isopropylsulfonyl-2-amino-6-[2-methyl-5-(2,4-difluorophenyl)imidazol-4-yl]benzimidazole

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of benzimidazoles and benzothiazoles as inhibitors of p-38 map kinase for treating metastasis or rheumatoid arthritis)


RN 660432-27-9 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[5-(2,4-difluorophenyl)-2-methyl-1-(phenylmethyl)-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)




RN 660432-69-9 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[4-phenyl-2-(2-thienyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 660432-74-6 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[2-(5-nitro-2-thienyl)-4-phenyl-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 660432-84-8 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[2-(4-nitrophenyl)-4-phenyl-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 660432-90-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-(4-fluorophenyl)-1H-imidazol-2-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 660432-91-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-phenyl-1H-imidazol-2-yl]-, phenylmethyl ester (CA INDEX NAME)




RN 660433-80-7 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)




RN 660433-82-9 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-(cyclopentylsulfonyl)-6-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 660433-93-2 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[4-(4-fluorophenyl)-2-(1-methylethyl)-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)




RN 660433-95-4 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[2-(1-methylethyl)-4-phenyl-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)




RN 660434-35-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-phenyl-1H-imidazol-1-yl]-, ethyl ester (CA INDEX NAME)




RN 660434-36-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-(4-fluorophenyl)-1H-imidazol-1-yl]-, ethyl ester (CA INDEX NAME)



RN 660434-54-8 CAPLUS


CN 1H-Benzimidazol-2-amine, 6-(1-cyclohexyl-4-phenyl-1H-imidazol-5-yl)-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 660434-58-2 CAPLUS


CN Carbamic acid, [4-[5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-phenyl-1H-imidazol-1-yl]cyclohexyl]-, 1,1-dimethylethyl ester

(9CI) (CA INDEX NAME)




RN 660434-59-3 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[1-(1,4-dioxaspiro[4.5]dec-8-yl)-4-phenyl-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)




RN 660434-73-1 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[1-[(4-methoxyphenyl)methyl]-4-phenyl-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)




RN 660434-87-7 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[1-cyclopropyl-4-(2-fluorophenyl)-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)




RN 660435-03-0 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[1-(4-nitrophenyl)-4-phenyl-1H-imidazol-5-yl]- (CA INDEX NAME)



RN 660435-18-7 CAPLUS




CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[4-phenyl-2-(4-piperidinyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 660435-21-2 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-[(1-methylethyl)sulfonyl]-6-[4-phenyl-1-(4-piperidinyl)-1H-imidazol-5-yl]- (CA INDEX NAME)









RN 660435-46-1 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[2-(4-chlorophenyl)-1-cyclopropyl-4-(2-fluorophenyl)-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)




RN 660435-50-7 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[1-cyclopropyl-4-(2-fluorophenyl)-2-[2-(trimethylsilyl)ethynyl]-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)




RN 660435-53-0 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[1-cyclopropyl-2-ethynyl-4-(2-fluorophenyl)-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)




RN 660435-63-2 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-(2-bromo-1-cyclohexyl-4-phenyl-1H-imidazol-5-yl)-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 660435-81-4 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[5-(2,4-difluorophenyl)-2-methyl-1H-imidazol-4-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



IT 660432-70-2P, 1-Isopropylsulfonyl-2-amino-6-[2-(thien-2-yl)-5-(phenyl)imidazol-4-yl]benzimidazole methanesulfonate  
 660432-71-3P, 1-Isopropylsulfonyl-2-amino-6-[2-(thien-2-yl)-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole 660432-72-4P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(thien-2-yl)-5-(3-trifluoromethylphenyl)imidazol-4-yl]benzimidazole 660432-73-5P  
 , 1-Isopropylsulfonyl-2-amino-6-[2-(thien-2-yl)-5-(4-trifluoromethylphenyl)imidazol-4-yl]benzimidazole 660432-75-7P  
 , 1-Isopropylsulfonyl-2-amino-6-[5-(phenyl)imidazol-4-yl]benzimidazole  
 660432-77-9P, 1-Isopropylsulfonyl-2-amino-6-[5-(4-fluorophenyl)imidazol-4-yl]benzimidazole bis(methanesulfonate)

660432-78-0P, 1-Isopropylsulfonyl-2-amino-6-[5-(3-trifluoromethylphenyl)imidazol-4-yl]benzimidazole 660432-79-1P  
, 1-Isopropylsulfonyl-2-amino-6-(2,5-diphenylimidazol-4-yl)benzimidazole  
660432-80-4P, 1-Isopropylsulfonyl-2-amino-6-[2-(2-chlorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660432-81-5P,  
1-Isopropylsulfonyl-2-amino-6-[2-(3-chlorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660432-82-6P,  
1-Isopropylsulfonyl-2-amino-6-[2-(4-chlorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660432-83-7P,  
1-Isopropylsulfonyl-2-amino-6-[2-(4-methoxyphenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660432-85-9P,  
1-Isopropylsulfonyl-2-amino-6-[2-(4-dimethylaminophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660432-86-0P,  
1-Isopropylsulfonyl-2-amino-6-[2-(pyridin-4-yl)-5-(phenyl)imidazol-4-yl]benzimidazole 660432-87-1P,  
1-Isopropylsulfonyl-2-amino-6-[2-(thiazol-2-yl)-5-(phenyl)imidazol-4-yl]benzimidazole 660432-88-2P,  
1-Isopropylsulfonyl-2-amino-6-[2-[1-(ethoxycarbonyl)ethen-2-yl]-5-(phenyl)imidazol-4-yl]benzimidazole 660432-91-7P,  
1-Isopropylsulfonyl-2-amino-6-[2-[1-(tert-butoxycarbonyl)piperidin-4-yl]-5-(phenyl)imidazol-4-yl]benzimidazole 660432-93-9P,  
1-Isopropylsulfonyl-2-amino-6-[2-(benzodioxol-5-yl)-5-(phenyl)imidazol-4-yl]benzimidazole methanesulfonate 660432-95-1P,  
1-Isopropylsulfonyl-2-amino-6-[2-[5-(ethyl)thiophen-2-yl]-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole methanesulfonate  
660432-96-2P, 1-Isopropylsulfonyl-2-amino-6-[2-(2,6-dichlorophenyl)-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole  
660432-97-3P, 1-Isopropylsulfonyl-2-amino-6-[2-(2,6-dichlorophenyl)-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole  
methanesulfonate 660432-98-4P,  
1-Isopropylsulfonyl-2-amino-6-[2-[4-(pyrrolidin-1-yl)phenyl]-5-(phenyl)imidazol-4-yl]benzimidazole 660432-99-5P,  
1-Isopropylsulfonyl-2-amino-6-[2-[2-(morpholin-4-yl)phenyl]-5-(phenyl)imidazol-4-yl]benzimidazole 660433-00-1P,  
1-Isopropylsulfonyl-2-amino-6-[2-[2-(4-methylpiperazin-1-yl)phenyl]-5-(phenyl)imidazol-4-yl]benzimidazole 660433-01-2P,  
1-Isopropylsulfonyl-2-amino-6-[2-(2,6-difluorophenyl)-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole 660433-03-4P,  
1-Isopropylsulfonyl-2-amino-6-[2-(2,4-difluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-04-5P,  
1-Isopropylsulfonyl-2-amino-6-[2-cyclohexyl-5-(phenyl)imidazol-4-yl]benzimidazole 660433-05-6P,  
1-Isopropylsulfonyl-2-amino-6-[2-cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole 660433-06-7P,  
1-Isopropylsulfonyl-2-amino-6-[2-tert-butyl-5-(phenyl)imidazol-4-yl]benzimidazole 660433-07-8P,  
1-Isopropylsulfonyl-2-amino-6-[2-(tetrahydropyran-4-yl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-08-9P,  
1-Isopropylsulfonyl-2-amino-6-[2-(tetrahydropyran-4-yl)-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole 660433-09-0P,  
1-Isopropylsulfonyl-2-amino-6-[2-(3,5-difluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-10-3P,  
1-Isopropylsulfonyl-2-amino-6-[2-(4-trifluoromethylphenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-11-4P,  
1-Isopropylsulfonyl-2-amino-6-[2-(2-trifluoromethoxyphenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-12-5P,  
1-Isopropylsulfonyl-2-amino-6-[2-(2,3-difluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-13-6P,  
1-Isopropylsulfonyl-2-amino-6-[2-(2-trifluoromethylphenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-15-8P,  
1-Isopropylsulfonyl-2-amino-6-[2-(4-tolylphenyl)-5-(phenyl)imidazol-4-

yl]benzimidazole bis(methanesulfonate) 660433-17-0P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(4-acetylaminophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole methanesulfonate 660433-18-1P,  
 1-Isopropylsulfonyl-2-amino-6-[2-tert-butyl-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole 660433-19-2P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[(benzyloxy)methyl]-5-(phenyl)imidazol-4-yl]benzimidazole 660433-21-6P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(thien-3-yl)-5-phenylimidazol-4-yl]benzimidazole bis(methanesulfonate) 660433-23-8P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(5-chlorothien-2-yl)-5-(phenyl)imidazol-4-yl]benzimidazole methanesulfonate 660433-25-0P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(5-chlorothien-2-yl)-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole methanesulfonate 660433-27-2P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(pyridin-3-yl)-5-(phenyl)imidazol-4-yl]benzimidazole bis(methanesulfonate) 660433-28-3P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(imidazol-2-yl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-29-4P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2-chloro-6-fluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-30-7P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2-chloro-6-fluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole bis(methanesulfonate) 660433-31-8P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2-chloro-6-fluorophenyl)-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole 660433-32-9P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2-chloro-6-fluorophenyl)-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole methanesulfonate 660433-33-0P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2-fluoro-6-trifluoromethylphenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-34-1P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2-fluoro-6-trifluoromethylphenyl)-5-(phenyl)imidazol-4-yl]benzimidazole methanesulfonate 660433-36-3P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2-fluoro-4-nitrophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole methanesulfonate 660433-38-5P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2,5-difluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole bis(methanesulfonate) 660433-40-9P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(4-chloro-2-fluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole methanesulfonate 660433-41-0P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2-chlorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole methanesulfonate 660433-43-2P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(4-trifluoromethoxyphenyl)-5-(phenyl)imidazol-4-yl]benzimidazole bis(methanesulfonate) 660433-45-4P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2-methylphenyl)-5-(phenyl)imidazol-4-yl]benzimidazole methanesulfonate 660433-47-6P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[4-[(methylsulfonyl)amino]phenyl]-5-(phenyl)imidazol-4-yl]benzimidazole methanesulfonate 660433-49-8P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(4-methylsulfonylphenyl)-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole bis(methanesulfonate) 660433-50-1P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2-fluoro-4-methylaminophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-52-3P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[2,6-difluoro-4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]-5-(phenyl)imidazol-4-yl]benzimidazole bis(methanesulfonate) 660433-53-4P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2-fluoro-4-aminophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660433-54-5P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[4-(ethylamino)phenyl]-5-(phenyl)imidazol-4-yl]benzimidazole 660433-57-8P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[4-[2-(piperidin-1-yl)ethoxy]phenyl]-5-(phenyl)imidazol-4-yl]benzimidazole trifluoroacetate 660433-59-0P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[4-[2-

(dimethylamino)ethoxy]phenyl]-5-(phenyl)imidazol-4-yl]benzimidazole  
 trifluoroacetate 660433-61-4P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[3-[2-(morpholino-4-yl)ethoxy]phenyl]-5-  
 (phenyl)imidazol-4-yl]benzimidazole trifluoroacetate  
 660433-63-6P, 1-Isopropylsulfonyl-2-amino-6-[2-[3-[2-(azepan-4-  
 yl)ethoxy]phenyl]-5-(phenyl)imidazol-4-yl]benzimidazole trifluoroacetate  
 660433-65-8P 660433-67-0P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[3-(2-dimethylaminoethoxy)phenyl]-5-  
 (phenyl)imidazol-4-yl]benzimidazole trifluoroacetate  
 660433-69-2P, 1-Isopropylsulfonyl-2-amino-6-[2-[3-[2-  
 (diethylamino)ethoxy]phenyl]-5-(phenyl)imidazol-4-yl]benzimidazole  
 trifluoroacetate 660433-71-6P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[3-[2-(piperidin-1-yl)ethoxy]phenyl]-5-  
 (phenyl)imidazol-4-yl]benzimidazole trifluoroacetate  
 660433-73-8P, 1-Isopropylsulfonyl-2-amino-6-[2-[4-[3-  
 (dimethylamino)propoxy]-3-fluorophenyl]-5-(phenyl)imidazol-4-  
 yl]benzimidazole trifluoroacetate 660433-75-0P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[3-fluoro-4-[2-(morpholino-4-  
 yl)ethoxy]phenyl]-5-(phenyl)imidazol-4-yl]benzimidazole trifluoroacetate  
 660433-77-2P, 1-Isopropylsulfonyl-2-amino-6-[2-[3-fluoro-4-[2-  
 (pyrrolidin-1-yl)ethoxy]phenyl]-5-(phenyl)imidazol-4-yl]benzimidazole  
 trifluoroacetate 660433-79-4P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2,6-difluorophenyl)-5-(phenyl)oxazol-4-  
 yl]benzimidazole 660433-81-8P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2,6-difluorophenyl)-5-(phenyl)imidazol-4-  
 yl]benzimidazole 1,5-naphthalenedisulfonate 660433-83-0P,  
 1-Cyclopentylsulfonyl-2-amino-6-[2-(2,6-difluorophenyl)-5-(phenyl)imidazol-  
 4-yl]benzimidazole bis(methanesulfonate) 660433-85-2P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(5-ethylthien-2-yl)-5-(phenyl)imidazol-4-  
 yl]benzimidazole methanesulfonate 660433-86-3P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2,6-dichlorophenyl)-5-(phenyl)imidazol-4-  
 yl]benzimidazole 660433-87-4P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2,6-dichlorophenyl)-5-(phenyl)imidazol-4-  
 yl]benzimidazole methanesulfonate 660433-88-5P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(3-trifluoromethylphenyl)-5-  
 (phenyl)imidazol-4-yl]benzimidazole 660433-90-9P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[2-(trifluoromethylsulfanyl)phenyl]-5-  
 (phenyl)imidazol-4-yl]benzimidazole bis(methanesulfonate)  
 660433-92-1P, 1-Isopropylsulfonyl-2-amino-6-[2-(3-methylthien-2-  
 yl)-5-(phenyl)imidazol-4-yl]benzimidazole methanesulfonate  
 660433-94-3P, 1-Isopropylsulfonyl-2-amino-6-[2-isopropyl-5-(4-  
 fluorophenyl)imidazol-4-yl]benzimidazole methanesulfonate  
 660433-96-5P, 1-Isopropylsulfonyl-2-amino-6-[2-isopropyl-5-  
 (phenyl)imidazol-4-yl]benzimidazole methanesulfonate  
 660433-98-7P, 1-Isopropylsulfonyl-2-amino-6-[2-(2,2-  
 dimethylpropyl)-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole  
 methanesulfonate 660434-00-4P,  
 1-Isopropylsulfonyl-2-amino-6-[2-methyl-5-(phenyl)imidazol-4-  
 yl]benzimidazole bis(methanesulfonate) 660434-02-6P,  
 1-Isopropylsulfonyl-2-amino-6-[2-methyl-5-(4-fluorophenyl)imidazol-4-  
 yl]benzimidazole methanesulfonate 660434-04-8P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(trifluoromethyl)-5-(phenyl)imidazol-4-  
 yl]benzimidazole methanesulfonate 660434-06-0P,  
 1-Isopropylsulfonyl-2-amino-6-[2-ethyl-5-(4-fluorophenyl)imidazol-4-  
 yl]benzimidazole methanesulfonate 660434-07-1P,  
 1-Isopropylsulfonyl-2-amino-6-[2-cyclopropyl-5-(4-fluorophenyl)imidazol-4-  
 yl]benzimidazole 660434-08-2P,  
 1-Isopropylsulfonyl-2-amino-6-[2-cyclopropyl-5-(4-fluorophenyl)imidazol-4-  
 yl]benzimidazole methanesulfonate 660434-10-6P,  
 1-[(Dimethylamino)sulfonyl]-2-amino-6-[2-(2,6-difluorophenyl)-5-  
 (phenyl)imidazol-4-yl]benzimidazole methanesulfonate

660434-11-7P, 1-Isopropylsulfonyl-2-amino-6-[2-formyl-5-(phenyl)imidazol-4-yl]benzimidazole 660434-13-9P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[(piperidin-1-yl)methyl]-5-(phenyl)imidazol-4-yl]benzimidazole 660434-15-1P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[(piperidin-1-yl)methyl]-5-(phenyl)imidazol-4-yl]benzimidazole methanesulfonate  
 660434-16-2P, 1-Isopropylsulfonyl-2-amino-6-[2-[[[2-(dimethylamino)ethyl](methyl)amino]methyl]-5-(phenyl)imidazol-4-yl]benzimidazole 660434-17-3P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[(morpholin-4-yl)methyl]-5-(phenyl)imidazol-4-yl]benzimidazole 660434-18-4P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[(dimethylamino)methyl]-5-(phenyl)imidazol-4-yl]benzimidazole 660434-19-5P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[N-[2-(piperidin-1-yl)ethyl]amino]methyl]-5-(phenyl)imidazol-4-yl]benzimidazole  
 660434-21-9P, 1-Isopropylsulfonyl-2-amino-6-[2-[[[2-(dimethylamino)ethyl]amino]methyl]-5-(phenyl)imidazol-4-yl]benzimidazole  
 660434-22-0P, 1-Isopropylsulfonyl-6-[2-(1-carboxyethyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660434-34-4P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(4-methoxybenzyl)-2-(hydroxymethyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-37-7P,  
 1-Isopropylsulfonyl-2-amino-6-[1-[1-(benzyl)piperidin-4-yl]-4-(phenyl)imidazol-5-yl]benzimidazole 660434-38-8P,  
 1-Isopropylsulfonyl-2-amino-6-[1-[1-(benzyl)piperidin-4-yl]-4-(4-fluorophenyl)imidazol-5-yl]benzimidazole 660434-39-9P,  
 1-Isopropylsulfonyl-2-amino-6-[1-methyl-4-(phenyl)imidazol-5-yl]benzimidazole 660434-40-2P,  
 1-Isopropylsulfonyl-2-amino-6-[1-[2-(hydroxy)ethyl]-4-(phenyl)imidazol-5-yl]benzimidazole 660434-41-3P,  
 1-Isopropylsulfonyl-2-amino-6-[1-[2-(methoxy)ethyl]-4-(phenyl)imidazol-5-yl]benzimidazole 660434-42-4P,  
 1-Isopropylsulfonyl-2-amino-6-[1-[2-[N-(tert-butoxycarbonyl)amino]ethyl]-4-(phenyl)imidazol-5-yl]benzimidazole 660434-43-5P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(cyclopropylmethyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-44-6P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)imidazol-5-yl]benzimidazole 660434-45-7P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(4-fluorobenzyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-46-8P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(2,4-difluorobenzyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-47-9P,  
 1-Isopropylsulfonyl-2-amino-6-[1-[(pyridin-2-yl)methyl]-4-(phenyl)imidazol-5-yl]benzimidazole 660434-48-0P,  
 1-Isopropylsulfonyl-2-amino-6-[1-[(pyridin-3-yl)methyl]-4-(phenyl)imidazol-5-yl]benzimidazole 660434-49-1P,  
 1-Isopropylsulfonyl-2-amino-6-[1-[(pyridin-4-yl)methyl]-4-(phenyl)imidazol-5-yl]benzimidazole 660434-50-4P,  
 1-Isopropylsulfonyl-2-amino-6-[1-[3-(phenyl)propan-1-yl]-4-(phenyl)imidazol-5-yl]benzimidazole 660434-51-5P,  
 1-Isopropylsulfonyl-2-amino-6-[1-[2-(morpholin-4-yl)ethyl]-4-(phenyl)imidazol-5-yl]benzimidazole 660434-52-6P,  
 1-Isopropylsulfonyl-2-amino-6-[1-[2-(morpholin-4-yl)ethyl]-4-(4-fluorophenyl)imidazol-5-yl]benzimidazole 660434-53-7P,  
 1-Isopropylsulfonyl-2-amino-6-[1-[3-(morpholin-4-yl)propan-1-yl]-4-(phenyl)imidazol-5-yl]benzimidazole 660434-55-9P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(trans-4-hydroxycyclohexyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-56-0P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(trans-4-hydroxycyclohexyl)-4-(4-fluorophenyl)imidazol-5-yl]benzimidazole 660434-60-6P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(tetrahydropyran-4-yl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-61-7P,

1-Isopropylsulfonyl-2-amino-6-[1-(2,2,6,6-tetramethylpiperidin-4-yl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-62-8P,  
1-Isopropylsulfonyl-2-amino-6-[1-(R)-3-hydroxypropan-2-yl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-63-9P,  
1-Isopropylsulfonyl-2-amino-6-[1-(S)-3-hydroxypropan-2-yl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-64-0P,  
1-Isopropylsulfonyl-2-amino-6-[1-(S)-3-hydroxypropan-2-yl)-4-(4-fluorophenyl)imidazol-5-yl]benzimidazole 660434-65-1P,  
1-Isopropylsulfonyl-2-amino-6-[1-isopropyl-4-(phenyl)imidazol-5-yl]benzimidazole 660434-66-2P,  
1-Isopropylsulfonyl-2-amino-6-[1-isopropyl-4-(4-fluorophenyl)imidazol-5-yl]benzimidazole 660434-67-3P,  
1-Isopropylsulfonyl-2-amino-6-[1-[2-(methoxycarbonyl)ethyl]-4-(phenyl)imidazol-5-yl]benzimidazole 660434-68-4P,  
1-Isopropylsulfonyl-2-amino-6-[1-(R)-1-phenyl-2-hydroxyethyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-69-5P,  
1-Isopropylsulfonyl-2-amino-6-[1-(trans-2-hydroxycyclohexyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-70-8P,  
1-Isopropylsulfonyl-2-amino-6-[1-(trans-2-hydroxymethylcyclohexyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-71-9P,  
1-Isopropylsulfonyl-2-amino-6-[1-(3-fluorobenzyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-72-0P,  
1-Isopropylsulfonyl-2-amino-6-[1-(2-fluorobenzyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-74-2P,  
1-Isopropylsulfonyl-2-amino-6-[1-(S)-1-cyclohexyl-3-hydroxypropan-2-yl)-4-(phenyl)imidazol-5-yl]benzimidazole 660434-75-3P,  
1-Isopropylsulfonyl-2-amino-6-[1-(trans-4-hydroxycyclohexyl)-4-(3-fluorophenyl)imidazol-5-yl]benzimidazole 660434-76-4P,  
1-Isopropylsulfonyl-2-amino-6-[1-(trans-4-hydroxycyclohexyl)-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660434-77-5P,  
1-Isopropylsulfonyl-2-amino-6-[1-methyl-4-(4-fluorophenyl)imidazol-5-yl]benzimidazole 660434-78-6P,  
1-Isopropylsulfonyl-2-amino-6-[1-ethyl-4-(phenyl)imidazol-5-yl]benzimidazole 660434-79-7P,  
1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-4-(phenyl)imidazol-5-yl]benzimidazole 660434-80-0P,  
1-Isopropylsulfonyl-2-amino-6-[1-cyclopentyl-4-(phenyl)imidazol-5-yl]benzimidazole 660434-81-1P,  
1-Isopropylsulfonyl-2-amino-6-[1-ethyl-4-(4-fluorophenyl)imidazol-5-yl]benzimidazole 660434-82-2P,  
1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-4-(4-fluorophenyl)imidazol-5-yl]benzimidazole 660434-83-3P,  
1-Isopropylsulfonyl-2-amino-6-[1-cyclopentyl-4-(4-fluorophenyl)imidazol-5-yl]benzimidazole 660434-84-4P,  
1-Isopropylsulfonyl-2-amino-6-[1-cyclohexyl-4-(4-fluorophenyl)imidazol-5-yl]benzimidazole 660434-85-5P,  
1-Isopropylsulfonyl-2-amino-6-[1-[(pyridin-3-yl)methyl]-4-(3-fluorophenyl)imidazol-5-yl]benzimidazole 660434-86-6P,  
1-Isopropylsulfonyl-2-amino-6-[1-[(pyridin-3-yl)methyl]-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660434-88-8P,  
1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-4-(3-fluorophenyl)imidazol-5-yl]benzimidazole 660434-89-9P,  
1-Isopropylsulfonyl-2-amino-6-[1-methyl-4-(2,4-difluorophenyl)imidazol-5-yl]benzimidazole 660434-90-2P,  
1-Isopropylsulfonyl-2-amino-6-[1-(trans-4-hydroxycyclohexyl)-4-(2,4-difluorophenyl)imidazol-5-yl]benzimidazole 660434-91-3P,  
1-Isopropylsulfonyl-2-amino-6-[1-cyclohexyl-4-(2,4-difluorophenyl)imidazol-5-yl]benzimidazole 660434-92-4P,  
1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-4-(2,4-difluorophenyl)imidazol-5-yl]benzimidazole 660434-93-5P,  
1-Isopropylsulfonyl-2-amino-6-[1-methyl-4-(2,3-difluorophenyl)imidazol-5-




yl]benzimidazole 660434-94-6P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(trans-4-hydroxycyclohexyl)-4-(2,3-difluorophenyl)imidazol-5-yl]benzimidazole 660434-96-8P  
 , 1-Isopropylsulfonyl-2-amino-6-[1-[1-(ethoxycarbonyl)piperidin-4-yl]-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole 660434-97-9P,  
 1-Isopropylsulfonyl-2-amino-6-[1-[1-(ethoxycarbonyl)piperidin-4-yl]-4-(3-fluorophenyl)imidazol-5-yl]benzimidazole 660434-98-0P,  
 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole methanesulfonate 660434-99-1P,  
 1-Isopropylsulfonyl-2-amino-6-[5-(3-fluorophenyl)imidazol-4-yl]benzimidazole 660435-00-7P,  
 1-Isopropylsulfonyl-2-amino-6-[5-(2-fluorophenyl)imidazol-4-yl]benzimidazole 660435-01-8P,  
 1-Isopropylsulfonyl-2-amino-6-[5-(2,4-fluorophenyl)imidazol-4-yl]benzimidazole 660435-02-9P,  
 1-Isopropylsulfonyl-2-amino-6-[5-(2,3-fluorophenyl)imidazol-4-yl]benzimidazole 660435-05-2P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(4-aminophenyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660435-06-3P,  
 1-Isopropylsulfonyl-2-amino-6-[2-methyl-4-(phenyl)thiazol-5-yl]benzimidazole 660435-08-5P,  
 1-Isopropylsulfonyl-2-amino-6-(2,4-diphenylthiazol-5-yl)benzimidazole 660435-09-6P, 2-Amino-6-[2-(2,6-difluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660435-10-9P,  
 2-Amino-6-[5-(phenyl)imidazol-4-yl]benzimidazole 660435-11-0P,  
 2-Amino-6-[2-(thien-2-yl)-5-(phenyl)imidazol-4-yl]benzimidazole 660435-12-1P, 1-Isopropylsulfonyl-2-amino-6-[2-(4-aminophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660435-13-2P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2-aminothien-5-yl)-5-(phenyl)imidazol-4-yl]benzimidazole 660435-14-3P,  
 1-Isopropylsulfonyl-2-amino-6-[1-methyl-2-(2,6-difluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole 660435-15-4P,  
 1-Isopropylsulfonyl-2-amino-6-[1-methyl-2-(2,6-difluorophenyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660435-16-5P,  
 1-Isopropylsulfonyl-2-amino-6-[1-methyl-2-(thien-2-yl)-5-(phenyl)imidazol-4-yl]benzimidazole 660435-17-6P,  
 1-Isopropylsulfonyl-2-amino-6-[1-methyl-2-(thien-2-yl)-4-(phenyl)imidazol-5-yl]benzimidazole 660435-20-1P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(piperidin-4-yl)-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole bis(trifluoroacetate) 660435-22-3P, 1-Isopropylsulfonyl-2-amino-6-[1-(piperidin-4-yl)-4-(4-fluorophenyl)imidazol-5-yl]benzimidazole 660435-23-4P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[1-(ethyl)piperidin-4-yl]-5-(phenyl)imidazol-4-yl]benzimidazole 660435-24-5P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(1-methylpiperidin-4-yl)-5-(phenyl)imidazol-4-yl]benzimidazole 660435-25-6P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[1-(3,3,3-trifluoropropyl)piperidin-4-yl]-5-(phenyl)imidazol-4-yl]benzimidazole 660435-26-7P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[1-(2-hydroxyethyl)piperidin-4-yl]-5-(phenyl)imidazol-4-yl]benzimidazole 660435-27-8P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[1-(benzyl)piperidin-4-yl]-5-(phenyl)imidazol-4-yl]benzimidazole 660435-28-9P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[1-(2-dimethylaminoethyl)piperidin-4-yl]-5-(phenyl)imidazol-4-yl]benzimidazole 660435-29-0P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[1-(isobutyl)piperidin-4-yl]-5-(phenyl)imidazol-4-yl]benzimidazole 660435-30-3P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[1-(isobutyl)piperidin-4-yl]-5-(4-fluorophenyl)imidazol-4-yl]benzimidazole 660435-31-4P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[1-(pyridin-2-yl-methyl)piperidin-4-yl]-5-(phenyl)imidazol-4-yl]benzimidazole 660435-32-5P,  
 1-Isopropylsulfonyl-2-amino-6-[2-[1-[(1-methyl-1H-imidazol-2-

yl)methyl]piperidin-4-yl]-5-(phenyl)imidazol-4-yl]benzimidazole  
 660435-33-6P, 1-Isopropylsulfonyl-2-amino-6-[1-[1-  
 (methyl)piperidin-4-yl]-4-(phenyl)imidazol-5-yl]benzimidazole  
 660435-34-7P, 1-Isopropylsulfonyl-2-amino-6-[1-(1-methylpiperidin-  
 4-yl)-4-(4-fluorophenyl)imidazol-5-yl]benzimidazole 660435-35-8P  
 , 1-Isopropylsulfonyl-2-amino-6-[1-[1-(isopropyl)piperidin-4-yl]-4-  
 (phenyl)imidazol-5-yl]benzimidazole 660435-37-0P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(4-hydroxycyclohexyl)-4-(phenyl)imidazol-  
 5-yl]benzimidazole 660435-38-1P,  
 1-Isopropylsulfonyl-2-amino-6-[1-(4-aminocyclohexyl)-4-(phenyl)imidazol-5-  
 yl]benzimidazole hydrochloride 660435-40-5P,  
 2-Benzylamino-6-[4-(phenyl)imidazol-5-yl]benzimidazole  
 660435-41-6P, 1-Isopropylsulfonyl-2-ethylamino-6-[2-(2,6-  
 difluorophenyl)-5-(phenyl)imidazol-4-yl]benzimidazole  
 660435-42-7P, 2-Ethylamino-6-[2-(2,6-difluorophenyl)-5-  
 (phenyl)imidazol-4-yl]benzimidazole 660435-43-8P,  
 1-Isopropylsulfonyl-6-[1-[4-(methoxy)benzyl]-4-(phenyl)imidazol-5-  
 yl]benzimidazole 660435-47-2P,  
 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-(4-chlorophenyl)-4-(2-  
 fluorophenyl)imidazol-5-yl]benzimidazole methanesulfonate  
 660435-49-4P, 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-(2,4-  
 difluorophenyl)-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole  
 methanesulfonate 660435-52-9P,  
 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-(3-butyln-1-yloxy)-4-(2-  
 fluorophenyl)imidazol-5-yl]benzimidazole methanesulfonate  
 660435-54-1P, 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-  
 (ethynyl)-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole methanesulfonate  
 660435-56-3P, 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-ethyl-  
 4-(2-fluorophenyl)imidazol-5-yl]benzimidazole methanesulfonate  
 660435-58-5P, 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-  
 ([1,2,3]triazol-4-yl)-4-(2-fluorophenyl)imidazol-5-yl]benzimidazole  
 methanesulfonate 660435-59-6P,  
 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-azido-4-(2-  
 fluorophenyl)imidazol-5-yl]benzimidazole 660435-61-0P,  
 1-Isopropylsulfonyl-2-amino-6-[1-cyclopropyl-2-amino-4-(2-  
 fluorophenyl)imidazol-5-yl]benzimidazole methanesulfonate  
 660435-64-3P, 1-Isopropylsulfonyl-2-amino-6-[1-cyclohexyl-2-  
 (ethynyl)-4-(phenyl)imidazol-5-yl]benzimidazole 660435-65-4P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(2,4-difluorophenyl)-5-(3,5-  
 difluorophenyl)imidazol-4-yl]benzimidazole 660435-66-5P,  
 1-Isopropylsulfonyl-2-amino-6-[2,5-bis(2,4-difluorophenyl)imidazol-4-  
 yl]benzimidazole 660435-68-7P,  
 1-Isopropylsulfonyl-2-amino-6-[2-(4-fluorophenyl)-5-(2-methyl-4-  
 fluorophenyl)imidazol-4-yl]benzimidazole methanesulfonate  
 660435-70-1P, 1-Isopropylsulfonyl-2-amino-6-[2-(4-fluorophenyl)-5-  
 (2-methylphenyl)imidazol-4-yl]benzimidazole methanesulfonate  
 660435-72-3P, 1-Isopropylsulfonyl-2-amino-6-[2-(4-fluorophenyl)-5-  
 (4-methylphenyl)imidazol-4-yl]benzimidazole methanesulfonate  
 660435-82-5P, 1-Isopropylsulfonyl-2-amino-6-[2-methyl-5-(2,4-  
 difluorophenyl)imidazol-4-yl]benzimidazole methanes

<-----User Break----->

(CA INDEX NAME)


Absolute stereochemistry.



RN 660434-63-9 CAPLUS

CN 1H-Imidazole-1-ethanol, 5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-β-methyl-4-phenyl-, (βS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660434-64-0 CAPLUS


CN 1H-Imidazole-1-ethanol, 5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-(4-fluorophenyl)-β-methyl-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 660434-65-1 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[1-(1-methylethyl)-4-phenyl-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)




RN 660434-66-2 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[4-(4-fluorophenyl)-1-(1-methylethyl)-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 660434-67-3 CAPLUS


CN 1H-Imidazole-1-propanoic acid, 5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-phenyl-, methyl ester (CA INDEX NAME)



RN 660434-68-4 CAPLUS

CN 1H-Imidazole-1-ethanol, 5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-β,4-diphenyl-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660434-69-5 CAPLUS

CN Cyclohexanol, 2-[5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-phenyl-1H-imidazol-1-yl]-, (1R,2R)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 660434-70-8 CAPLUS


CN Cyclohexanemethanol, 2-[5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-phenyl-1H-imidazol-1-yl]-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 660434-71-9 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[1-[(3-fluorophenyl)methyl]-4-phenyl-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 660434-72-0 CAPLUS


CN 1H-Benzimidazol-2-amine, 6-[1-[(2-fluorophenyl)methyl]-4-phenyl-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 660434-74-2 CAPLUS

CN 1H-Imidazole-1-ethanol, 5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-β-(cyclohexylmethyl)-4-phenyl-, (βS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660434-75-3 CAPLUS

CN Cyclohexanol, 4-[5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-(3-fluorophenyl)-1H-imidazol-1-yl]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 660434-76-4 CAPLUS


CN Cyclohexanol, 4-[5-[2-amino-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-6-yl]-4-(2-fluorophenyl)-1H-imidazol-1-yl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 660434-77-5 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-[4-(4-fluorophenyl)-1-methyl-1H-imidazol-5-yl]-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)




RN 660434-78-6 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-(1-ethyl-4-phenyl-1H-imidazol-5-yl)-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 660434-79-7 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-(1-cyclopropyl-4-phenyl-1H-imidazol-5-yl)-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 660434-80-0 CAPLUS

CN 1H-Benzimidazol-2-amine, 6-(1-cyclopentyl-4-phenyl-1H-imidazol-5-yl)-1-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

=>

<-----User Break----->

=> d bib hitstr 7

L7 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2003:777523 CAPLUS

DN 139:307756

TI 4,5-Dihydro-1H-pyrazole derivatives useful as mitotic kinesin inhibitors,



and their pharmaceutical compositions and use in the treatment of cancer  
 IN Breslin, Michael J.; Coleman, Paul J.; Cox, Christopher D.; Culberson, J.  
 Christopher; Hartman, George D.; Mariano, Brenda J.; Torrent, Maricel  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 159 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003079973	A2	20031002	WO 2003-US6403	20030304 <--
	WO 2003079973	A3	20041111		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2478068	A1	20031002	CA 2003-2478068	20030304 <--
	AU 2003249597	A1	20031008	AU 2003-249597	20030304 <--
	AU 2003249597	B2	20070628		
	EP 1492487	A2	20050105	EP 2003-745083	20030304
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005526091	T	20050902	JP 2003-577806	20030304
	US 20050119484	A1	20050602	US 2004-506702	20040907 <--
PRAI	US 2002-362922P	P	20020308		
	WO 2003-US6403	W	20030304		

OS MARPAT 139:307756


IT 609813-26-5P, 3-(2,5-Difluorophenyl)-N,N-dimethyl-5-(benzimidazol-6-yl)-4,5-dihydro-1H-pyrazole-1-carboxamide  
 609813-86-7P, 3-(2,5-Difluorophenyl)-N,N-dimethyl-5-(3-aminopropyl)-5-(benzimidazol-6-yl)-4,5-dihydro-1H-pyrazole-1-carboxamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of dihydropyrazole derivs. as mitotic kinesin inhibitors for use as anticancer agents)

RN 609813-26-5 CAPLUS

CN 1H-Pyrazole-1-carboxamide, 5-(1H-benzimidazol-6-yl)-3-(2,5-difluorophenyl)-4,5-dihydro-N,N-dimethyl- (CA INDEX NAME)



RN 609813-86-7 CAPLUS  
 CN 1H-Pyrazole-1-carboxamide, 5-(3-aminopropyl)-5-(1H-benzimidazol-6-yl)-3-(2,5-difluorophenyl)-4,5-dihydro-N,N-dimethyl- (CA INDEX NAME)




OSC.G 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (29 CITINGS)  
 RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 8-17

L7 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2003:396884 CAPLUS  
 DN 138:401735  
 TI Preparation of phenyl substituted triazoles as selective inhibitors of  
 ALK5 kinase  
 IN Gaster, Laramie Mary; Harling, John David; Heer, Jag Paul; Heightman,  
 Thomas Daniel; Payne, Andrew Hele  
 PA Smithkline Beecham Corporation, USA  
 SO PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003042211	A1	20030522	WO 2002-EP13482	20021114 <--	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	CA 2467267	A1	20030522	CA 2002-2467267	20021114 <--	
	AU 2002363603	A1	20030526	AU 2002-363603	20021114 <--	
	EP 1444232	A1	20040811	EP 2002-803039	20021114 <--	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK		
	BR 2002014160	A	20040928	BR 2002-14160	20021114 <--	
	HU 2004002227	A2	20050228	HU 2004-2227	20021114	
	CN 1608065	A	20050420	CN 2002-825914	20021114	

JP 2005518352 T 20050623 JP 2003-544047 20021114  
 IN 2004DN01253 A 20061222 IN 2004-DN1253 20040511  
 US 20050014938 A1 20050120 US 2004-495414 20040513 <--  
 MX 2004004593 A 20040813 MX 2004-4593 20040514 <--  
 NO 2004002244 A 20040713 NO 2004-2244 20040528 <--  
 ZA 2004003487 A 20060531 ZA 2004-3487 20060330  
 PRAI GB 2001-27430 A 20011115  
 WO 2002-EP13482 W 20021114  
 OS MARPAT 138:401735  
 IT 528892-29-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of Ph substituted triazoles as selective inhibitors of ALK5  
 kinase)  
 RN 528892-29-7 CAPLUS  
 CN 1H-Benzimidazole, 6-[5-(3-chlorophenyl)-1H-1,2,3-triazol-4-yl]-1-methyl-  
 (CA INDEX NAME)




OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)  
 RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2002:849613 CAPLUS  
 DN 137:353066  
 TI Preparation of nitrogenous fused-ring compound having pyrazolyl group as  
 substituents as inhibitors of activation of signal transduction and  
 activation of transcription (STAT6) protein  
 IN Yoshida, Ichiro; Yoneda, Naoki; Ohashi, Yoshiaki; Suzuki, Shuichi;  
 Miyamoto, Mitsuaki; Miyazaki, Futoshi; Seshimo, Hidenori; Kamata, Junichi;  
 Takase, Yasutaka; Shirato, Manabu; Shimokubo, Daiya; Sakuma, Yoshinori;  
 Yokohama, Hiromitsu  
 PA Eisai Co., Ltd., Japan  
 SO PCT Int. Appl., 1006 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002088107	A1	20021107	WO 2002-JP4156	20020425 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,			

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2002253596 A1 20021111 AU 2002-253596 20020425 <--  
 EP 1382603 A1 20040121 EP 2002-722791 20020425 <--  
 EP 1382603 B1 20080723  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 AT 402164 T 20080815 AT 2002-722791 20020425  
 ES 2310202 T3 20090101 ES 2002-722791 20020425  
 EP 2048142 A2 20090415 EP 2008-13159 20020425  
 EP 2048142 A3 20090422  
 R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,  
 NL, PT, SE, TR  
 JP 4310109 B2 20090805 JP 2002-585407 20020425  
 US 7074801 B1 20060711 US 2003-475585 20031023 <--  
 PRAI JP 2001-129959 A 20010426  
 EP 2002-722791 A3 20020425  
 WO 2002-JP4156 W 20020425  
 OS MARPAT 137:353066  
 IT 474695-63-1P 474695-71-1P 474695-74-4P  
 474695-75-5P 474695-76-6P 474695-77-7P  
 474695-78-8P 474695-79-9P 474695-80-2P  
 474695-81-3P 474701-68-3P 474701-69-4P  
 474701-70-7P 474701-71-8P 474701-72-9P  
 474706-30-4P 474706-31-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of (N-containing heterocyclyl)pyrazole as inhibitors of  
 activation  
 of STAT6 protein and/or IL-4 and/or IL-13 signal transduction as  
 preventives and/or remedies of diseases)  
 RN 474695-63-1 CAPLUS  
 CN 1H-Benzimidazole, 1-(4-fluorophenyl)-6-[3-(4-fluorophenyl)-1H-pyrazol-4-  
 yl]-, hydrochloride (1:2) (CA INDEX NAME)




RN 474695-71-1 CAPLUS

CN 1H-Benzimidazol-2-amine, 1-(4-fluorophenyl)-6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 474695-74-4 CAPLUS

CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-(2-pyridinyl)- (CA INDEX NAME)




RN 474695-75-5 CAPLUS


CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, hydrochloride (1:3) (CA INDEX NAME)



RN 474695-76-6 CAPLUS  
 CN 3-Pyridinecarboxitrile, 6-[6-[3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, hydrochloride (1:3) (CA INDEX NAME)




RN 474695-77-7 CAPLUS  
 CN 3-Pyridinecarbonitrile, 6-[6-[3-(4-cyanophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 474695-78-8 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[6-[3-(4-cyanophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 474695-79-9 CAPLUS  
 CN 3-Pyridinecarbonitrile, 6-[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 474695-80-2 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[6-[3-(3-cyanophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 474695-81-3 CAPLUS


CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1-[5-(methylsulfonyl)-2-thienyl]-, hydrochloride (1:2) (CA INDEX NAME)






● 2 HCl

RN 474701-68-3 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 474701-69-4 CAPLUS  
 CN Methanone, [6-[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-3-pyridinyl]-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)

 $\bullet 2 \text{ HCl}$ 

RN 474701-70-7 CAPLUS


CN	Methanone, [6-[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-3-pyridinyl](3-methoxy-1-pyrrolidinyl)-, hydrochloride (1:2) (CA INDEX NAME)
----	--



● 2 HCl

RN 474701-71-8 CAPLUS


CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-6-[6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N-methyl-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 474701-72-9 CAPLUS


CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2,6-difluorophenyl)-1H-pyrazol-4-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 474706-30-4 CAPLUS

CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2,4-difluorophenyl)-1H-pyrazol-4-yl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 474706-31-5 CAPLUS  
 CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2-fluorophenyl)-1H-pyrazol-4-yl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

IT	474701-59-2P	474701-60-5P	474701-61-6P
	474701-62-7P	474701-63-8P	474706-26-8P
	474706-27-9P	474707-04-5P	474707-06-7P
	474707-07-8P	474709-99-4P	474710-00-4P
	474710-01-5P	474711-65-4P	474711-70-1P
	474711-73-4P	474711-74-5P	474711-75-6P
	474711-76-7P	474711-77-8P	474711-78-9P
	474711-79-0P	474711-82-5P	474711-83-6P
	474711-84-7P	474712-65-7P	474712-66-8P
	474712-67-9P		


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (N-containing heterocyclyl)pyrazole as inhibitors of activation

of STAT6 protein and/or IL-4 and/or IL-13 signal transduction as preventives and/or remedies of diseases)


RN 474701-59-2 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-, ethyl ester (CA INDEX NAME)




RN 474701-60-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 474701-61-6 CAPLUS

CN 3-Pyridinecarboxamide, 6-[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 474701-62-7 CAPLUS

CN Methanone, [6-[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-3-pyridinyl]-4-morpholinyl- (CA INDEX NAME)




RN 474701-63-8 CAPLUS

CN Methanone, [6-[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-3-pyridinyl](3-methoxy-1-pyrrolidinyl)- (CA INDEX NAME)




RN 474706-26-8 CAPLUS

CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2,4-difluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 474706-27-9 CAPLUS


CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



RN 474707-04-5 CAPLUS  
 CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 474707-06-7 CAPLUS  
 CN Propanoic acid, 2,2-dimethyl-, [6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]methyl ester (CA INDEX NAME)




RN 474707-07-8 CAPLUS  
 CN Propanoic acid, 2,2-dimethyl-, [5-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]methyl ester (CA INDEX NAME)






RN 474709-99-4 CAPLUS

CN 1H-Benzimidazole, 6-[3-(2,6-difluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 474710-00-4 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [6-[3-(2,6-difluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]methyl ester (CA INDEX NAME)




RN 474710-01-5 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [5-[3-(2,6-difluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]methyl ester (CA INDEX NAME)




RN 474711-65-4 CAPLUS

CN 1H-Benzimidazole, 1-(4-fluorophenyl)-6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)




RN 474711-70-1 CAPLUS

CN 1H-Benzimidazole, 6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1-(2-pyridinyl)- (CA INDEX NAME)




RN 474711-73-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylthio)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 474711-74-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[5-[3-[4-(methylthio)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 474711-75-6 CAPLUS


CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylsulfinyl)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)



RN 474711-76-7 CAPLUS  
 CN 3-Pyridinecarboxamide, 6-[6-[3-[4-(methylsulfonyl)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 474711-77-8 CAPLUS  
 CN 3-Pyridinecarbonitrile, 6-[6-[3-[4-(methylthio)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 474711-78-9 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[6-[3-[4-(methylsulfonyl)phenyl]-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 474711-79-0 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[6-[3-(4-cyanophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 474711-82-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[6-[3-(4-cyanophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 474711-83-6 CAPLUS

CN 3-Pyridinecarboxamide, 6-[5-[3-(4-cyanophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 474711-84-7 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]- (CA INDEX NAME)




RN 474712-65-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-6-[6-[3-(4-fluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-1H-benzimidazol-1-yl]-N-methyl- (CA INDEX NAME)




RN 474712-66-8 CAPLUS

CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-6-[3-(2,6-difluorophenyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



RN 474712-67-9 CAPLUS  
 CN 1H-Benzimidazole, 1-(5-chloro-2-pyridinyl)-5-[3-(2,6-difluorophenyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



OSC.G 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)  
 RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2002:793608 CAPLUS  
 DN 137:310917  
 TI Aromatic-substituted thiohydantoin, their preparation, and their use for  
 treating diabetes, dyslipidemia, and obesity  
 IN Boubia, Benaïssa; Chaput, Evelyne; Ou, Khan; Ratel, Philippe  
 PA Laboratoires Fournier SA, Fr.  
 SO PCT Int. Appl., 111 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA French  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002081453	A1	20021017	WO 2002-FR1167	20020404 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ,				
<-----User Break----->				

=> d bib hitstr 10-17

L7 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2002:793608 CAPLUS  
 DN 137:310917




TI Aromatic-substituted thiohydantoins, their preparation, and their use for  
treating diabetes, dyslipidemia, and obesity  
IN Boubia, Benaïssa; Chaput, Evelyne; Ou, Khan; Ratel, Philippe  
PA Laboratoires Fournier SA, Fr.  
SO PCT Int. Appl., 111 pp.  
CODEN: PIXXD2


DT Patent  
LA French

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002081453	A1	20021017	WO 2002-FR1167	20020404 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR 2823209	A1	20021011	FR 2001-4552	20010404 <--
	FR 2823209	B1	20031212		
	CA 2444024	A1	20021017	CA 2002-2444024	20020404 <--
	AU 2002302676	A1	20021021	AU 2002-302676	20020404 <--
	EP 1373219	A1	20040102	EP 2002-730333	20020404 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EE 200300485	A	20040216	EE 2003-485	20020404 <--
	CN 1500081	A	20040526	CN 2002-807581	20020404 <--
	BR 2002007910	A	20040803	BR 2002-7910	20020404 <--
	JP 2004525175	T	20040819	JP 2002-579441	20020404 <--
	HU 2004001537	A2	20050128	HU 2004-1537	20020404
	HU 2004001537	A3	20050628		
	ZA 2003007372	A	20040922	ZA 2003-7372	20030922 <--
	US 20040116417	A1	20040617	US 2003-473032	20030926 <--
	NO 2003004430	A	20031006	NO 2003-4430	20031003 <--
	MX 2003009083	A	20041122	MX 2003-9083	20031003 <--
	BG 108225	A	20050430	BG 2003-108225	20031003
PRAI	FR 2001-4552	A	20010404		
	WO 2002-FR1167	W	20020404		
OS	MARPAT 137:310917				
IT	471934-58-4P, 1-(4-(Morpholin-4-yl)phenyl)-3-(1H-benzimidazol-5-yl)-5-methyl-2-thioxo-4-imidazolidinone 471934-59-5P, 1-(4-(Morpholin-4-yl)phenyl)-3-(1H-benzimidazol-5-yl)-5-ethyl-2-thioxo-4-imidazolidinone 471934-60-8P, 1-(4-(Morpholin-4-yl)phenyl)-3-(1H-benzimidazol-5-yl)-5-propyl-5-(hydroxy)-2-thioxo-4-imidazolidinone				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of aromatic-substituted thiohydantoins for treatment of diabetes, dyslipidemia, and obesity)				
RN	471934-58-4 CAPLUS				
CN	4-Imidazolidinone, 3-(1H-benzimidazol-6-yl)-5-methyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo- (CA INDEX NAME)				



RN 471934-59-5 CAPLUS  
 CN 4-Imidazolidinone, 3-(1H-benzimidazol-6-yl)-5-ethyl-1-[4-(4-morpholinyl)phenyl]-2-thioxo- (CA INDEX NAME)



RN 471934-60-8 CAPLUS  
 CN 4-Imidazolidinone, 3-(1H-benzimidazol-6-yl)-5-hydroxy-1-[4-(4-morpholinyl)phenyl]-5-propyl-2-thioxo- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2002:695955 CAPLUS  
 DN 137:232650

TI Preparation of nitrogen-containing heteroaryl compounds having HIV integrase inhibitory activity

IN Fuji, Masahiro; Mikamiyama, Hidenori; Murai, Hitoshi

PA Shionogi & Co., Ltd., Japan

SO PCT Int. Appl., 316 pp.

CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070486	A1	20020912	WO 2002-JP1778	20020227 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,			

UG, US, UZ, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2439666 A1 20020912 CA 2002-2439666 20020227 <--  
 AU 2002234901 A1 20020919 AU 2002-234901 20020227 <--  
 EP 1375486 A1 20040102 EP 2002-701583 20020227 <--  
 EP 1375486 B1 20081015  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 BR 2002007809 A 20040309 BR 2002-7809 20020227 <--  
 JP 3616628 B2 20050202 JP 2002-569806 20020227  
 CN 1659143 A 20050824 CN 2002-808921 20020227  
 HU 2004000175 A2 20070730 HU 2004-175 20020227  
 AT 411292 T 20081015 AT 2002-701583 20020227  
 EP 2033952 A1 20090311 EP 2008-166487 20020227  
 R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,  
 NL, PT, SE, TR, SI  
 ZA 2003006113 A 20040810 ZA 2003-6113 20030807 <--  
 US 20040127708 A1 20040701 US 2003-469364 20030818 <--  
 US 7148237 B2 20061212  
 IN 2003CN01325 A 20051125 IN 2003-CN1325 20030822  
 MX 2003007765 A 20031208 MX 2003-7765 20030828 <--  
 NO 2003003848 A 20031030 NO 2003-3848 20030829 <--  
 JP 2004175807 A 20040624 JP 2004-27473 20040204 <--  
 US 20060293334 A1 20061228 US 2006-500387 20060808 <--  
 PRAI JP 2001-57037 A 20010301  
 JP 2001-243530 A 20010810  
 JP 2001-395022 A 20011226  
 EP 2002-701583 A3 20020227  
 JP 2002-569806 A3 20020227  
 WO 2002-JP1778 W 20020227  
 US 2003-469364 A3 20030818  
 OS MARPAT 137:232650  
 IT 457945-40-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of nitrogen-containing heteroaryl compds. having HIV integrase  
 inhibitory activity)  
 RN 457945-40-3 CAPLUS  
 CN 1H-Benzimidazol-4-ol, 7-chloro-2-methyl-5-(5-phenyl-1,3,4-oxadiazol-2-yl)-  
 (CA INDEX NAME)



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)  
 RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2002:487553 CAPLUS

DN 137:47200  
 TI Aryl or heteroaryl fused imidazoles as selective GABAA receptor ligands  
 IN Li, Guiying; Peterson, John M.; Albaugh, Pamela; Currie, Kevin S.; Cai, Guolin; Gustavson, Linda M.; Lee, Kyungae; Hutchison, Alan; Singh, Vinod; Maynard, George D.; Yuan, Jun; Ling, Hong Xie; Ghosh, Manuka; Liu, Nian; Luke, George P.; Mitchell, Scott; Allen, Martin Patrick; Liras, Spiros  
 PA Neurogen Corporation, USA; Pfizer Inc.  
 SO PCT Int. Appl., 309 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050062	A2	20020627	WO 2001-US50038	20011221 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2431592	A1	20020627	CA 2001-2431592	20011221 <--
	AU 2002032768	A	20020701	AU 2002-32768	20011221 <--
	US 20030069257	A1	20030410	US 2001-38069	20011221 <--
	US 6916819	B2	20050712		
	EP 1368342	A2	20031210	EP 2001-992307	20011221 <--
	EP 1368342	B1	20050907		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EE 200300304	A	20031215	EE 2003-304	20011221 <--
	EE 5108	B1	20081215		
	HU 2003003849	A2	20040301	HU 2003-3849	20011221 <--
	CN 1553909	A	20041208	CN 2001-822386	20011221 <--
	JP 2004536782	T	20041209	JP 2002-551558	20011221 <--
	AT 304008	T	20050915	AT 2001-992307	20011221
	BR 2001016385	A	20051213	BR 2001-16385	20011221
	AP 1503	A	20060228	AP 2003-2818	20011221
	W: GM, GH, KE, LS, MW, MZ, SL, SD, SZ, TZ, UG, ZM, ZW				
	ES 2256325	T3	20060716	ES 2001-992307	20011221
	NZ 526330	A	20060929	NZ 2001-526330	20011221
	AU 2002232768	B2	20070906	AU 2002-232768	20011221
	IN 2003KN00740	A	20060310	IN 2003-KN740	20030609
	BG 107899	A	20040831	BG 2003-107899	20030611 <--
	ZA 2003004544	A	20050407	ZA 2003-4544	20030611
	MX 2003005493	A	20040420	MX 2003-5493	20030618 <--
	NO 2003002834	A	20030808	NO 2003-2834	20030620 <--
	NO 326558	B1	20090112		
	KR 854174	B1	20080826	KR 2003-708480	20030621
	US 20060025425	A1	20060202	US 2005-179458	20050712 <--
	US 7300945	B2	20071127		
	US 20080227793	A1	20080918	US 2007-942480	20071119 <--
PRAI	US 2000-257492P	P	20001221		
	US 2001-38069	A3	20011221		
	WO 2001-US50038	W	20011221		
	US 2005-179458	A3	20050712		
OS	MARPAT 137:47200				
IT	438553-71-0P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU				

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of aryl or heteroaryl fused imidazoles as selective GABAA receptor ligands)

RN 438553-71-0 CAPLUS

CN 1H-Benzimidazole, 2-[[1-(2,5-difluorophenyl)-1H-pyrazol-5-yl]methyl]-1-ethyl-5-[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)



OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)

L7 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2001:886830 CAPLUS

DN 136:20093

TI Synthesis of cyclic and bicyclic diamino histamine-3 receptor antagonists  
IN Bennani, Youssef L.; Black, Lawrence A.; Dwight, Wesley J.; Faghieh, Ramin; Gentles, Robert G.; Liu, Huaqing; Phelan, Kathleen M.; Vasudevan, Anil; Zhang, Henry Q.

PA Abbott Laboratories, USA

SO U.S. Pat. Appl. Publ., 82 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20010049367	A1	20011206	US 2001-799450	20010305 <--
	US 6559140	B2	20030506		
PRAI	US 2000-187933P	P	20000309		
OS	MARPAT 136:20093				
IT	360552-47-2P				



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; cyclic and bicyclic diamino histamine-3 receptor antagonists)

RN 360552-47-2 CAPLUS

CN 2-Furancarboxamide, N-[(1S)-2-[4-[3-[4-[5-(1H-benzimidazol-6-yl)-1,2,4-oxadiazol-3-yl]-3-fluorophenoxy]propyl]hexahydro-1H-1,4-diazepin-1-yl]-1-methyl-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L7 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2001:333637 CAPLUS

DN 134:326523

TI Preparation of oxazoline antiproliferative agents

IN Gwaltney, Stephen L., II; Jae, Hwan-Soo; Kalvin, Douglas M.; Liu, Gang; Sham, Hing L.; Li, Qun; Claiborne, Akiyo K.; Wang, Le; Barr, Kenneth J.; Woods, Keith W.

PA Abbott Laboratories, USA

SO U.S., 32 pp.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6228868	B1	20010508	US 1999-360463	19990723 <--
PRAI	US 1998-94241P	P	19980727		
OS	MARPAT 134:326523				
IT	256935-53-2P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of substituted oxazolines as antiproliferative agents)				
RN	256935-53-2	CAPLUS			
CN	1H-Benzimidazole, 5-[4,5-dihydro-5-(3,4,5-trimethoxyphenyl)-2-oxazolyl]-1,2-dimethyl- (CA INDEX NAME)				



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)  
 RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2001:12273 CAPLUS

DN 134:86271

TI Preparation of pyrimidine derivatives as Src-family protein tyrosine kinase inhibitor compounds

IN Armstrong, Helen M.; Beresis, Richard; Goulet, Joung L.; Holmes, Mark A.; Hong, Xingfang; Mills, Sander G.; Parsons, William H.; Sinclair, Peter J.; Steiner, Mark G.; Wong, Frederick; Zaller, Dennis M.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 470 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001000213	A1	20010104	WO 2000-US17443	20000626 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2383546	A1	20010104	CA 2000-2383546	20000626 <--
	EP 1206265	A1	20020522	EP 2000-941701	20000626 <--
	EP 1206265	B1	20031112		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	US 6498165	B1	20021224	US 2000-604305	20000626 <--
	JP 2003523942	T	20030812	JP 2001-505922	20000626 <--
	AT 253915	T	20031115	AT 2000-941701	20000626 <--
PRAI	US 1999-141639P	P	19990630		
	WO 2000-US17443	W	20000626		

OS MARPAT 134:86271


IT 317826-56-5P, 2-[(S)-1-Phenylethylamino]-4-[6-(4-phenyl-1,2,3-triazol-1-yl)benzimidazol-1-yl]pyrimidine 317828-76-5P, 2-[(S)-1-Phenylethylamino]-4-[5-(6-phenylpyridazin-3-yl)benzimidazol-1-yl]pyrimidine

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as Src-family protein tyrosine kinase inhibitor compds.)


RN 317826-56-5 CAPLUS  
CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[6-(4-phenyl-1H-1,2,3-triazol-1-yl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 317828-76-5 CAPLUS  
CN 2-Pyrimidinamine, N-[(1S)-1-phenylethyl]-4-[5-(6-phenyl-3-pyridazinyl)-1H-benzimidazol-1-yl]- (CA INDEX NAME)

Absolute stereochemistry.




OSC.G 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)  
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 1999:96030 CAPLUS  
DN 130:139342  
TI Preparation of arylbenzimidazoles and analogs as interleukin 1 $\beta$  inhibitors  
IN De Nanteuil, Guillaume; Portevin, Bernard; Bonnet, Jacqueline; Fradin, Armel  
PA Adir et Compagnie, Fr.  
SO Eur. Pat. Appl., 21 pp.  
CODEN: EPXXDW  
DT Patent  
LA French  
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------



PI	EP 894795	A1	19990203	EP 1998-401920	19980728 <--
	EP 894795	B1	20010606		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	FR 2766822	A1	19990205	FR 1997-9710	19970730 <--
	FR 2766822	B1	20010223		
	US 6040327	A	20000321	US 1998-120487	19980722 <--
	JP 11100368	A	19990413	JP 1998-210640	19980727 <--
	ES 2159922	T3	20011016	ES 1998-401920	19980728 <--
	CA 2244438	A1	19990130	CA 1998-2244438	19980729 <--
	NO 9803493	A	19990201	NO 1998-3493	19980729 <--
	CN 1210859	A	19990317	CN 1998-117575	19980729 <--
	CN 1087740	C	20020717		
	ZA 9806814	A	19990202	ZA 1998-6814	19980730 <--
	AU 9878608	A	19990211	AU 1998-78608	19980730 <--
	AU 734447	B2	20010614		
	BR 9802804	A	20000502	BR 1998-2804	19980730 <--
	HU 9801725	A1	20001128	HU 1998-1725	19980730 <--
	HK 1018440	A1	20021101	HK 1999-103381	19990805 <--
	GR 3036473	T3	20011130	GR 2001-401332	20010830 <--
PRAI	FR 1997-9710	A	19970730		
OS	MARPAT 130:139342				
IT	220067-11-8P 220067-12-9P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of arylbenzimidazoles and analogs as interleukin 1 $\beta$ inhibitors)				
RN	220067-11-8 CAPLUS				
CN	1H-Benzimidazole, 2-(phenoxyethyl)-6-(4-phenyl-1H-imidazol-1-yl)- (CA INDEX NAME)				



RN	220067-12-9	CAPLUS
CN	1H-Benzimidazole-2-methanol, 6-(4-phenyl-1H-imidazol-1-yl)-, hydrochloride (1:2) (CA INDEX NAME)	



● 2 HCl

OSC.G	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1977:568033 CAPLUS  
 DN 87:168033  
 OREF 87:26559a,26562a  
 TI (1H-Benzimidazol-2-yl)carbamates  
 IN Raeymaekers, Alfons H. M.; Van Gelder, Jozef H. L.  
 PA Janssen Pharmaceutica N. V., Belg.  
 SO U.S., 6 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4032536	A	19770628	US 1976-707750	19760722 <--
	AU 7725205	A	19781123	AU 1977-25205	19770517 <--
	JP 61056235	B	19861201	JP 1977-73403	19770622 <--
	GB 1581454	A	19801217	GB 1977-26743	19770627 <--
	NL 7708116	A	19780124	NL 1977-8116	19770721 <--
	FR 2359138	A1	19780217	FR 1977-22397	19770721 <--
	FR 2359138	B1	19800222		
	ZA 7704418	A	19790228	ZA 1977-4418	19770721 <--
	HU 173881	B	19790928	HU 1977-JA791	19770721 <--
	SU 662012	A3	19790505	SU 1977-2504518	19770722 <--
PRAI	US 1976-707750	A	19760722		


OS MARPAT 87:168033

IT 64420-40-2P 64420-41-3P 64420-42-4P  
 64420-43-5P 64420-44-6P 64420-50-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation and anthelmintic activity of)


RN 64420-40-2 CAPLUS

CN Carbamic acid, N-[6-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]-1H-benzimidazol-2-yl]-, methyl ester (CA INDEX NAME)




RN 64420-41-3 CAPLUS

CN Carbamic acid, [5-(2-phenyl-1,3-dioxolan-2-yl)-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 64420-42-4 CAPLUS

CN Carbamic acid, [5-(4-methyl-2-phenyl-1,3-dioxolan-2-yl)-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 64420-43-5 CAPLUS

CN Carbamic acid, [5-(4,5-dimethyl-2-phenyl-1,3-dioxolan-2-yl)-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 64420-44-6 CAPLUS

CN Carbamic acid, [5-(4-methyl-2-phenyl-1,3-dioxan-2-yl)-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 64420-50-4 CAPLUS

CN Carbamic acid, [5-(5,5-dimethyl-2-phenyl-1,3-dioxan-2-yl)-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

FILE 'REGISTRY' ENTERED AT 11:43:27 ON 19 AUG 2009

L1 STRUC  
L2 50 S L1  
L3 STRUC  
L4 27 S L3  
L5 12899 S L3 FUL

FILE 'CAPLUS' ENTERED AT 11:45:53 ON 19 AUG 2009

L6 2734 S L5  
L7 259 S L6 AND KINASE  
L8 27 S L7 AND P38  
L9 7 S L8 AND PY<=2004

FILE 'STNGUIDE' ENTERED AT 11:51:27 ON 19 AUG 2009

FILE 'REGISTRY' ENTERED AT 11:53:16 ON 19 AUG 2009

L10 12500 S L5 AND (IMIDAZ? OR OXAZO? OR ISOXAZO? OR THIAZOL?)

FILE 'CAPLUS' ENTERED AT 11:53:59 ON 19 AUG 2009

L11 2710 S L10  
L12 29 S L11 AND P38  
L13 22 S L12 NOT L9  
L14 1 S L13 AND PY<=2004

=> s l13 not l14

L15 21 L13 NOT L14

=> d bib 1-21

L15 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2009:739059 CAPLUS

DN 151:86657

TI Combinations of therapeutic agents comprising vascular disrupting agent  
such as 5,6-dimethylxanthenone-4-acetic acid, for treating cancer

IN Evans, Dean Brent; Jacques, Christian J.

PA Novartis A.-G., Switz.

SO PCT Int. Appl., 57pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009076170	A2	20090618	WO 2008-US85535	20081204
	WO 2009076170	A3	20090730		
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	US 2007-13335P	P	20071213		

L15 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:229214 CAPLUS  
 DN 150:306641  
 TI Preparation of pyrazolyl phenyl ureas as enzyme modulators  
 IN Flynn, Daniel L.; Petillo, Peter A.  
 PA Deciphera Pharmaceuticals, LLC, USA  
 SO U.S. Pat. Appl. Publ., 536pp., Cont. of U. S. Ser. No. 318,399.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080113967	A1	20080515	US 2007-963740	20071221
	US 20070078121	A1	20070405	US 2005-318399	20051223
PRAI	US 2004-638968P	P	20041223		
	US 2004-638986P	P	20041223		
	US 2004-638987P	P	20041223		
	US 2004-639087P	P	20041223		
	US 2005-318399	A1	20051223		
OS	MARPAT 150:306641				

L15 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:3913 CAPLUS  
 DN 150:90455  
 TI Method for predicting biological systems responses in hepatocytes  
 IN Irwin, William; Verneti, Lawrence; Johnston, Patricia A.; Taylor, D. Lansing  
 PA Cellumen, Inc., USA  
 SO PCT Int. Appl., 70pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009002565	A1	20081231	WO 2008-US8105	20080626
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2007-946186P	P	20070626		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:1481200 CAPLUS  
 DN 150:29003  
 TI NF- $\kappa$ B inhibitor- p38 MAP kinase inhibitor combination for the treatment of cancer and inflammatory diseases  
 IN Fu, Haiyan; Liotta, Dennis C.; Thomas, Shala L.; Snyder, James P.  
 PA Emory University, USA  
 SO PCT Int. Appl., 122pp.

CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008150899	A1	20081211	WO 2008-US65132	20080529
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2007-932125P P 20070529

OS MARPAT 150:29003

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2008:1164070 CAPLUS  
DN 151:139281  
TI Comparative molecular field analysis (CoMFA) for p38 inhibitors  
AU Nayana, Munuganti Ravi Shashi; Sekhar, Yadavalli Nataraja  
CS Bioinformatics Division, Environmental Microbiology Lab, Department of Botany, Osmania University, Hyderabad, 500007, India  
SO Internet Electronic Journal of Molecular Design (2007), 6(12), 385-395  
CODEN: IEJMAT; ISSN: 1538-6414  
URL: [http://biochempress.com/Files/iejmd\\_2007\\_6\\_0385.pdf](http://biochempress.com/Files/iejmd_2007_6_0385.pdf)  
PB BioChem Press  
DT Journal; (online computer file)  
LA English

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2008:191704 CAPLUS  
DN 148:233389  
TI Method for predicting biological systems responses  
IN Giuliano, Kenneth; Gough, Albert; Johnston, Patricia; Taylor, D. Lansing  
PA Cellumen, Inc., USA  
SO PCT Int. Appl., 52pp.  
CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008018905	A2	20080214	WO 2007-US1217	20070117
	WO 2008018905	A3	20080522		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,			

RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,  
 TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA  
 EP 1984737 A2 20081029 EP 2007-835667 20070117  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
 BA, HR, MK, RS  
 JP 2009526519 T 20090723 JP 2008-550465 20070117  
 CN 101395472 A 20090325 CN 2007-80007435 20080901  
 US 20090170091 A1 20090702 US 2009-87809 20090206  
 PRAI US 2006-759476P P 20060117  
 US 2006-846006P P 20060920  
 WO 2007-US1217 W 20070117

L15 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:160612 CAPLUS  
 DN 148:215061  
 TI Preparation of 2-heterocyclyl-1,3,4-oxadiazole derivatives as glycogen  
 synthase kinase-3 $\beta$  (GSK-3 $\beta$ ) inhibitors  
 IN Itoh, Fumio; Kunitomo, Jun; Kobayashi, Hiromi; Kimura, Eiji; Saitoh,  
 Morihisa; Kawamoto, Tomohiro; Iwashita, Hiroki; Murase, Katsuhito  
 PA Takeda Pharmaceutical Company Limited, Japan  
 SO PCT Int. Appl., 531pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008016123	A1	20080207	WO 2007-JP65203	20070802
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	JP 2006-212642	A	20060803		
OS	MARPAT 148:215061				
OSC.G	1			THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)	
RE.CNT	230			THERE ARE 230 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT	

L15 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:26083 CAPLUS  
 DN 148:205319  
 TI Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent  
 p38 $\alpha$  MAP kinase inhibitors with excellent in vivo  
 antiinflammatory properties  
 AU Mader, Mary; de Dios, Alfonso; Shih, Chuan; Bonjouklian, Rosanne; Li,  
 Tiechao; White, Wesley; Lopez de Uralde, Beatriz; Sanchez-Martinez,  
 Concepcion; del Prado, Miriam; Jaramillo, Carlos; de Diego, Eugenio;

Martin Cabrejas, Luisa M.; Dominguez, Carmen; Montero, Carlos; Shepherd, Timothy; Dally, Robert; Toth, John E.; Chatterjee, Arindam; Pleite, Sehila; Blanco-Urgoiti, Jaime; Perez, Leticia; Barberis, Mario; Lorite, Maria Jose; Jambrina, Enrique; Nevill, C. Richard; Lee, Paul A.; Schultz, Richard C.; Wolos, Jeffrey A.; Li, Li C.; Campbell, Robert M.; Anderson, Bryan D.

CS Centro de Investigacion, Lilly S.A., Eli Lilly and Co., Madrid, 28108, Spain  
 SO Bioorganic & Medicinal Chemistry Letters (2008), 18(1), 179-183  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 148:205319  
 OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)  
 RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2007:1425431 CAPLUS  
 DN 148:45779  
 TI Method of treating inflammatory diseases using tyrosine kinase inhibitors  
 IN Robinson, William H.; Paniagua, Ricardo T.  
 PA The Board of Trustees of the Leland Stanford Junior University, USA  
 SO PCT Int. Appl., 84pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007143146	A2	20071213	WO 2007-US13033	20070531
	WO 2007143146	A3	20090723		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 20080032989	A1	20080207	US 2007-809515	20070531
	EP 2076266	A2	20090708	EP 2007-809286	20070531
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
PRAI	US 2006-810030P	P	20060531		
	WO 2007-US13033	W	20070531		

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L15 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2007:814248 CAPLUS  
 DN 147:211866  
 TI Thiazole compounds as protein kinase B inhibitors and their preparation, pharmaceutical compositions and use in the treatment of PKB-mediated diseases  
 IN Zeng, Qingping; Allen, John G.; Bourbeau, Matthew P.; Dominguez, Celia;



Fotsch, Christopher H.; Han, Nianhe; Hong, Fang-Tsao; Huang, Xin; Lee, Matthew R.; Li, Aiwen; Liu, Qingyian; Rider, James T.; Tadesse, Seifu; Tasker, Andrew S.; Viswanadhan, Vellarkad N.; Wang, Xianghong; Weiler, Kurt E.; Wohlhieter, George E.; Yao, Guomin; Yuan, Chester Chenguang

PA Amgen Inc., USA

SO PCT Int. Appl., 319pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007084391	A2	20070726	WO 2007-US871	20070111
	WO 2007084391	A3	20080320		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2007207743	A1	20070726	AU 2007-207743	20070111
	CA 2636077	A1	20070726	CA 2007-2636077	20070111
	US 20070173506	A1	20070726	US 2007-652728	20070111
	US 7514566	B2	20090407		
	EP 1981884	A2	20081022	EP 2007-718125	20070111
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
	JP 2009525960	T	20090716	JP 2008-551297	20070111
	MX 2008009048	A	20080722	MX 2008-9048	20080714
	IN 2008CN03974	A	20090313	IN 2008-CN3974	20080729
	KR 2008091369	A	20081010	KR 2008-719941	20080814
	NO 2008003572	A	20081017	NO 2008-3572	20080818
	CN 101421265	A	20090429	CN 2007-80009708	20080918
PRAI	US 2006-759546P	P	20060118		
	WO 2007-US871	W	20070111		
OS	MARPAT 147:211866				

L15 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2007:782351 CAPLUS

DN 147:291498

TI Oridonin induced L929 cell death partially through TNF $\alpha$  signal pathway

AU Huang, Jian; Wu, Lijun; Tashiro, Shinichi; Onodera, Satoshi; Ikejima, Takashi

CS China-Japan Research Institute of Medical and Pharmaceutical Sciences, Shenyang Pharmaceutical University, Shenyang, 110016, Peop. Rep. China

SO Zhongguo Yaolixue Tongbao (2006), 22(4), 471-475

CODEN: ZYTOE8; ISSN: 1001-1978

PB Anhui Yike Daxue Linchuan Yaoli Yanjiuso

DT Journal

LA Chinese

L15 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:1190047 CAPLUS

DN 146:92615  
 TI Discovery and design of benzimidazolone based inhibitors of p38  
 MAP kinase  
 AU Hammach, Abdelhakim; Barbosa, Antonio; Gaenzler, Faith Corbo; Fadra,  
 Tazmeen; Goldberg, Daniel; Hao, Ming-Hong; Kroe, Rachel R.; Liu, Pingrong;  
 Qian, Kevin C.; Ralph, Mark; Sarko, Christopher; Soleymanzadeh, Fariba;  
 Moss, Neil  
 CS Departments of Medicinal Chemistry and Biologics and Biomolecular  
 Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT,  
 06877, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2006), 16(24), 6316-6320  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 146:92615  
 OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)  
 RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:844728 CAPLUS  
 DN 145:271809  
 TI Piperazine-piperidines with CXCR3 antagonist activity and their  
 preparation, pharmaceutical compositions, and their use for treatment of  
 chemokine mediated diseases  
 IN Yu, Wensheng; Kim, Seong Heon; Anilkumar, Gopinadhan N.; Rosenblum, Stuart  
 B.; Shankar, Bandarpalle B.; McGuinness, Brian F.; Hobbs, Douglas W.;  
 Shao, Yuefei  
 PA Schering Corporation, USA; Pharmacopeia Drug Discovery, Inc.  
 SO PCT Int. Appl., 102pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006088836	A2	20060824	WO 2006-US5121	20060214
	WO 2006088836	A3	20061102		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	CA 2598489	A1	20060824	CA 2006-2598489	20060214
	US 20060276457	A1	20061207	US 2006-353806	20060214
	EP 1858895	A2	20071128	EP 2006-734999	20060214
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	JP 2008530212	T	20080807	JP 2007-556234	20060214
	MX 2007010068	A	20071010	MX 2007-10068	20070816
	CN 101189238	A	20080528	CN 2006-80012630	20071016
PRAI	US 2005-653378P	P	20050216		

WO 2006-US5121 W 20060214  
 OS CASREACT 145:271809; MARPAT 145:271809  
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:763835 CAPLUS  
 DN 145:202872  
 TI Treatment of metastasized tumors  
 IN Lopes De Menezes, Daniel; Heise, Carla; Xin, Xiaohua  
 PA Chiron Corporation, USA  
 SO PCT Int. Appl., 101pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006081445	A2	20060803	WO 2006-US2979	20060127
	WO 2006081445	A3	20070111		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2006208012	A1	20060803	AU 2006-208012	20060127
	CA 2596084	A1	20060803	CA 2006-2596084	20060127
	US 20060183750	A1	20060817	US 2006-342257	20060127
	EP 1845990	A2	20071024	EP 2006-733986	20060127
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	JP 2008528617	T	20080731	JP 2007-553278	20060127
	MX 2007009099	A	20070913	MX 2007-9099	20070727
	ZA 2007006871	A	20081029	ZA 2007-6871	20070816
	KR 2007118596	A	20071217	KR 2007-719428	20070824
	NO 2007004360	A	20071025	NO 2007-4360	20070827
	CN 101146538	A	20080319	CN 2006-80009463	20070924
PRAI	US 2005-647568P	P	20050127		
	US 2005-669245P	P	20050406		
	US 2005-722053P	P	20050929		
	WO 2006-US2979	W	20060127		

OS MARPAT 145:202872  
 OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:349551 CAPLUS  
 DN 145:62826  
 TI Synthesis of imidazole based p38 MAP (mitogen-activated protein) kinase inhibitors under buffered conditions  
 AU Magnus, Nicholas A.; Diserod, William D.; Nevill, C. Richard, Jr.; Wepsiec, James P.  
 CS Chemical Product Research and Development Division, Eli Lilly and Company,

Indianapolis, IN, 46285, USA  
 SO Organic Process Research & Development (2006), 10(3), 556-560  
 CODEN: OPRDFK; ISSN: 1083-6160  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 145:62826  
 RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:343955 CAPLUS  
 DN 144:390936

TI Aryl nitrogen-containing bicyclic compounds and their preparation,  
 pharmaceutical compositions, and protein kinase inhibitory activity and  
 use in prophylaxis and treatment of kinase-mediated diseases  
 IN Patel, Vinod F.; Kim, Joseph L.; Geuns-Meyer, Stephanie D.; Chaffee,  
 Stuart C.; Cee, Victor J.; Hodous, Brian L.; Bellon, Steven; Harmange,  
 Jean-Christophe; Olivieri, Philip R.; Thaman, Maya C.; Dimauro, Erin F.;  
 Buchanan, John L.; McGowan, David C.; Albrecht, Brian K.; Deak, Holly L.;  
 Bemis, Jean E.; White, Ryan; Martin, Matthew W.; Habgood, Gregory J.;  
 Tempest, Paul A.; Masse, Craig E.; Buckner, William H.; Herberich, Bradley  
 J.; Graceffa, Russell; Zhang, Dawei; Xu, Shimin; Sham, Kelvin; Rzasa,  
 Robert M.; Falsey, James Richard; Chakrabarti, Partha P.; Cao, Guo-Qiang;  
 Tomlinson, Susan Ann; Pettus, Liping H.; Smith, Adrian Leonard; Paras,  
 Nick A.; Liu, Gang; Demorin, Frenel F.; Tasker, Andrew; Reed, Anthony

PA Amgen Inc., USA  
 SO PCT Int. Appl., 876 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006039718	A2	20060413	WO 2005-US35873	20051003
	WO 2006039718	A3	20060713		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 20070054916	A1	20070308	US 2005-240590	20050930
	AU 2005292152	A1	20060413	AU 2005-292152	20051003
	CA 2582029	A1	20060413	CA 2005-2582029	20051003
	EP 1836174	A2	20070926	EP 2005-818381	20051003
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	JP 2008515812	T	20080515	JP 2007-534914	20051003
	MX 2007003784	A	20070424	MX 2007-3784	20070329
PRAI	US 2004-61535P	P	20041001		
	US 2005-240590	A	20050930		
	WO 2005-US35873	W	20051003		
OS	CASREACT 144:390936; MARPAT 144:390936				

OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L15 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:962247 CAPLUS

DN 143:266919

TI Preparation of benzimidazole compounds as p38 kinase inhibitors  
for the treatment of cancer

IN Bonjouklian, Rosanne; Dally, Robert Dean; De Dios, Alfonso; Del Prado  
Catalina, Miriam Filadelfa; Dominguez-Fernandez, Carmen; Jaramillo Aguado,  
Carlos; Lopez de Uralde-Garmendia, Beatriz; Montero Salgado, Carlos;  
Shepherd, Timothy Alan

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005080380	A1	20050901	WO 2005-US24	20050121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1720862	A1	20061115	EP 2005-711246	20050121
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	US 20080227839	A1	20080918	US 2006-597359	20060721
PRAI	EP 2004-380022	A	20040203		
	US 2004-563399P	P	20040419		
	WO 2005-US24	W	20050121		

OS CASREACT 143:266919; MARPAT 143:266919

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:704222 CAPLUS

DN 143:326257

TI Theoretical and Experimental Design of Atypical Kinase Inhibitors:  
Application to p38 MAP Kinase

AU McClure, Kim F.; Abramov, Yuriy A.; Laird, Ellen R.; Barberia, John T.;  
Cai, Weiling; Carty, Thomas J.; Cortina, Santo R.; Danley, Dennis E.;  
Dipesa, Alan J.; Donahue, Kathleen M.; Dombroski, Mark A.; Elliott, Nancy  
C.; Gabel, Christopher A.; Han, Seungil; Hynes, Thomas R.; LeMotte, Peter  
K.; Mansour, Mahmoud N.; Marr, Eric S.; Letavic, Michael A.; Pandit,  
Jayvardhan; Ripin, David B.; Sweeney, Francis J.; Tan, Douglas; Tao, Yong  
CS Groton Laboratories, Pfizer Global Research and Development, Groton, CT,  
06340, USA

SO Journal of Medicinal Chemistry (2005), 48(18), 5728-5737

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 143:326257

OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:588664 CAPLUS

DN 143:91021

TI Methods of treating acute inflammation in animals with p38 MAP  
kinase inhibitors

IN Kehrl, Marcus Eugene, Jr.; Sakya, Subas Man

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005060967	A1	20050707	WO 2004-IB4035	20041206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004305318	A1	20050707	AU 2004-305318	20041206
	CA 2550064	A1	20050707	CA 2004-2550064	20041206
	EP 1708709	A1	20061011	EP 2004-801341	20041206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1893950	A	20070110	CN 2004-80037773	20041206
	BR 2004017674	A	20070320	BR 2004-17674	20041206
	JP 2007514730	T	20070607	JP 2006-544579	20041206
	US 20050153985	A1	20050714	US 2004-14392	20041216
	IN 2006DN02752	A	20070810	IN 2006-DN2752	20060516
	ZA 2006004926	A	20071128	ZA 2006-4926	20060614
	KR 2006120205	A	20061124	KR 2006-711930	20060616
	MX 2006007023	A	20060831	MX 2006-7023	20060619
	NO 2006003300	A	20060914	NO 2006-3300	20060717
PRAI	US 2003-530722P	P	20031218		
	WO 2004-IB4035	W	20041206		

OS MARPAT 143:91021

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:159128 CAPLUS

DN 142:348138

TI Design of Potent and Selective 2-Aminobenzimidazole-Based p38  
 $\alpha$  MAP Kinase Inhibitors with Excellent in Vivo Efficacy

AU de Dios, Alfonso; Shih, Chuan; Lopez de Uralde, Beatriz; Sanchez, Concepcion; del Prado, Miriam; Cabrejas, Luisa M. Martin; Pleite, Sehila; Blanco-Urgoiti, Jaime; Lorite, Maria Jose; Nevill, C. Richard, Jr.; Bonjouklian, Rosanne; York, Jeremy; Vieth, Michal; Wang, Yong; Magnus, Nicholas; Campbell, Robert M.; Anderson, Bryan D.; McCann, Denis J.;

Giera, Deborah D.; Lee, Paul A.; Schultz, Richard M.; Li, Li C.; Johnson, Lea M.; Wolos, Jeffrey A.  
 CS Lilly S.A., Eli Lilly and Co., Alcobendas, Madrid, 28108, Spain  
 SO Journal of Medicinal Chemistry (2005), 48(7), 2270-2273  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 142:348138  
 OSC.G 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)  
 RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2005:99470 CAPLUS  
 DN 142:197889  
 TI Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases  
 IN Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott  
 PA Bayer Pharmaceuticals Corporation, USA  
 SO PCT Int. Appl., 68 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009961	A2	20050203	WO 2004-US23500	20040722
	WO 2005009961	A3	20050331		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004259760	A1	20050203	AU 2004-259760	20040722
	CA 2532865	A1	20050203	CA 2004-2532865	20040722
	US 20050038080	A1	20050217	US 2004-895985	20040722
	EP 1663978	A2	20060607	EP 2004-786091	20040722
	EP 1663978	B1	20071128		
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004012219	A	20060822	BR 2004-12219	20040722
	CN 1856469	A	20061101	CN 2004-80021091	20040722
	JP 2006528196	T	20061214	JP 2006-521221	20040722
	ES 2297490	T3	20080501	ES 2004-786091	20040722
	ZA 2006000609	A	20070530	ZA 2006-609	20060120
	KR 2006052866	A	20060519	KR 2006-701558	20060123
	MX 2006000860	A	20060720	MX 2006-860	20060123
	IN 2006DN00402	A	20070824	IN 2006-DN402	20060123
	NO 2006000870	A	20060407	NO 2006-870	20060222
PRAI	US 2003-489102P	P	20030723		
	US 2004-540326P	P	20040202		
	WO 2004-US23500	W	20040722		
OS	CASREACT 142:197889				
OSC.G	15				THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)

RE.CNT 4      THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT